Compositions and methods for targeted depletion, enrichment, and fragmentation of nucleic acids using CRISPR / Cas system proteins

Through the CRISPR/Cas system protein-gRNA complex cleavage and segmentation technology, the problem of low proportion of microbial DNA in high host DNA samples was solved, and efficient microbial DNA enrichment and metagenomic analysis resolution were achieved.

CN114438169BActive Publication Date: 2024-11-08ARC BIO LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111423939.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2015-07-28
Filing Date
2015-12-19
Publication Date
2024-11-08
Estimated Expiration
2035-12-19

AI Technical Summary

Technical Problem

The prior art is difficult to effectively reduce the proportion of microbial DNA in high host DNA samples, resulting in high cost and low resolution of metagenomic sequencing, especially when the content of microbial DNA in the samples is low.

Method used

The CRISPR/Cas system protein-gRNA complex is used to contact the sample, and the proportion of microbial DNA is increased by targeted cleavage and segmentation or enrichment of microbial DNA, including contacting the sample with multiple CRISPR/Cas system protein-gRNA complexes, and cleavage The sequence is targeted and treated by linker-specific PCR amplification and exonuclease treatment to remove the target sequence.

Benefits of technology

The proportion of microbial DNA is significantly increased, the sequencing cost is reduced, and the resolution of metagenomic analysis is improved, especially in high-host DNA samples, which enhances the detection ability of microbial DNA.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114438169B_ABST
    Figure CN114438169B_ABST
Patent Text Reader

Abstract

Provided herein are methods and compositions for eliminating targeted nucleic acid sequences from a sample, enriching a target sequence from a sample, and / or segmenting a sequence from a sample. In one aspect, provided herein are methods for enriching a target sequence of a sample, comprising: (a) providing a sample comprising a target sequence and a sequence targeted to be eliminated, wherein the target sequence accounts for less than 30% of the sample; (b) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to the targeting sequence, and thereby cutting the targeting sequence. In one embodiment disclosed herein, the method further comprises extracting the target sequence and the sequence targeted to be eliminated from the sample.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese patent application No. 201580076214.X (application date: December 19, 2015, invention name: Compositions and methods for targeted elimination, enrichment, and segmentation of nucleic acids using CRISPR / Cas system proteins).

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority to U.S. Provisional Application Serial No. 62 / 094,980, filed on December 20, 2014, and U.S. Provisional Application Serial No. 62 / 198,097, filed on July 28, 2015. The contents of these applications are incorporated herein by reference in their entirety. Background of the Invention

[0005] Many human clinical DNA samples or sample libraries (such as cDNA libraries derived from RNA) or from tissues, DNA samples extracted from fluids or other host material samples contain highly abundant sequences, whose information value is very small and increase sequencing costs. Although methods for subtracting these sequences (such as by hybrid capture) have been developed, these methods are usually time-consuming and may be inefficient. In addition, hybrid capture usually seeks to capture the DNA target sequence while discarding the remaining sequence. Therefore, when the DNA target sequence is unknown in advance (such as when screening samples to study all microorganisms or non-host DNA sequences), the subtraction captured by hybridization is not a feasible option.

[0006] Although shotgun sequencing of human samples can be performed to study microbial DNA, the low levels of microbial DNA in many samples preclude shotgun sequencing of many complex and / or targeted samples due to cost. This is true, for example, for metagenomic analysis of samples where the samples contain organisms of more than one species (eukaryotic, prokaryotic, or viral organisms). For example, a DNA library derived from whole blood typically contains >99% human DNA. Therefore, in order to detect infectious agents circulating in human blood from shotgun sequencing, sequencing to very high coverage is required to ensure adequate coverage. The large costs associated with sequencing high human DNA samples therefore provide relatively little metagenomic data. Therefore, many human tissue DNA samples are considered unsuitable for metagenomic sequencing simply because the data yield is low compared to the required resources. Therefore, there is a need in the art to increase the yield of microbial DNA in high host DNA samples, particularly when measuring high host endogenous (HHE) DNA samples, to increase the percentage of microbial DNA to be sequenced.

[0007] Recent advances in DNA extraction have provided some sequencing technologies, thus pointing the focus of the field of metagenomics from PCR-amplified 16S ribosomal RNA markers to shotgun sequencing of entire metagenomes. However, due to the low percentage of microbial DNA in the overall sample material, shotgun sequencing may produce suboptimal results when sequencing HHE DNA samples. In addition, shotgun sequencing often does not provide enough information to achieve accurate resolution in metagenomic analysis, especially when the selected molecules (e.g., 16S ribosomal RNA) represent only a single lineage. In addition, 16S ribosomal RNA lineages often cannot distinguish pathogens from non-pathogenic strains of closely related bacteria, which is a key goal of clinical metagenomic analysis.

[0008] In contrast, the use of whole genome DNA and RNA sequences is preferred for metagenomic analysis because it provides information of the entire metagenome. Therefore, there is a need in the art to provide DNA and RNA sequencing technologies for metagenomic analysis to obtain improved resolution. For example, whole genome analysis of the metagenomes of fecal materials from obese and normal weight patients revealed highly reproducible differences in microbial community structure. These materials tend to have very high microbial DNA content (>99% of microorganisms and <1% of humans).

[0009] In contrast, sequencing libraries derived from many other tissues, including human blood, vagina, nasal mucosa, and lung, typically contain >90% human DNA and <10% microbial DNA. Although samples with <10% microbial DNA can still be sequenced to obtain sufficient information for metagenomic analysis, the amount of sequencing required for specimens with less target DNA is expensive and therefore unsustainable for many researchers.

[0010] Therefore, there is a need in the art to obtain low-cost, efficient methods and compositions for metagenomic analysis. Such methods and compositions are provided herein.

[0011] All patents, patent applications, publications, documents, web links and articles cited herein are hereby incorporated by reference in their entirety.

[0012] Brief description of the invention

[0013] Provided herein are methods and compositions for depleting targeted nucleic acid sequences from a sample, enriching a sequence of interest from a sample, and / or partitioning a sequence from a sample. The methods and compositions are applicable to biological, clinical, forensic, and environmental samples.

[0014] In one aspect, a method for enriching a sample for a target sequence is provided, comprising: (a) providing a sample comprising a target sequence and a sequence targeted for elimination, wherein the target sequence accounts for less than 30% of the sample; (b) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to the targeting sequence and thereby cuts the targeting sequence. In one embodiment disclosed herein, the method further comprises extracting the target sequence and the sequence targeted for elimination from the sample. In one embodiment disclosed herein, the method further comprises fragmenting the extracted sequence. In one embodiment disclosed herein, the method further comprises connecting the 5' and 3' end adapters of the fragmented extracted sequence. In one embodiment disclosed herein, the cut targeting sequence is removed by size exclusion. In one embodiment disclosed herein, the cut targeting sequence is removed by using biotin. In one embodiment disclosed herein, the method further comprises amplifying the target sequence. In one embodiment disclosed herein, the sequence targeted for elimination is followed by a protospacer adjacent motif or (PAM) sequence. In one embodiment disclosed herein, the method comprises amplifying the target sequence with at least 10 2A unique CRISPR / Cas system protein-gRNA complex is contacted with a sample. In one embodiment disclosed herein, the sample is any one of a biological sample, a clinical sample, a forensic sample, or an environmental sample. In one embodiment disclosed herein, the sample comprises a host nucleic acid sequence and a non-host nucleic acid sequence of interest that are targeted to be eliminated. In one embodiment disclosed herein, the non-host nucleic acid sequence includes a microbial nucleic acid sequence. In one embodiment disclosed herein, the microbial nucleic acid sequence is a bacterial, viral, or eukaryotic parasitic nucleic acid sequence. In one embodiment disclosed herein, the sample is contacted with a CRISPR / Cas system protein-gRNA complex, wherein the gRNA is complementary to the DNA corresponding to the ribosomal RNA sequence. In one embodiment disclosed herein, the sample is contacted with a CRISPR / Cas system protein-gRNA complex, wherein the gRNA is complementary to mitochondrial DNA. In one embodiment disclosed herein, the sample is contacted with a CRISPR / Cas system protein-gRNA complex, wherein the gRNA is complementary to a sequence encoding a globin, a sequence encoding a transposon, a sequence encoding a retroviral sequence, a sequence comprising a telomeric sequence, a sequence comprising a subtelomeric repeat, a sequence comprising a centromere sequence, a sequence comprising an intronic sequence, a sequence comprising an Alu repeat, a sequence comprising a SINE repeat, a sequence comprising a LINE repeat, a sequence comprising a double nucleic acid repeat, a sequence comprising a trinucleic acid repeat, a sequence comprising a tetranucleic acid repeat, a sequence comprising a poly A repeat, a sequence comprising a poly T repeat, a sequence comprising a poly C repeat, a sequence comprising a poly G repeat, a sequence comprising an AT-rich sequence, or a sequence comprising a GC-rich sequence. In one embodiment disclosed herein, the extracted nucleic acid includes any one of single-stranded DNA, double-stranded DNA, single-stranded RNA, double-stranded RNA, cDNA, synthetic DNA, artificial DNA, and a DNA / RNA hybrid. In one embodiment disclosed herein, the target sequence accounts for less than 10% of the extracted nucleic acid. In one embodiment disclosed herein, the target sequence accounts for less than 5% of the extracted nucleic acid. In one embodiment disclosed herein, the CRISPR / Cas system protein is Cas9, Cpf1, Cas3, Cas8a-c, Cas10, Cse1, Csy1, Csn2, Cas4, Csm2, or Cm5. In one embodiment disclosed herein, the CRISPR / Cas system protein is Cas9. In one embodiment disclosed herein, the CRISPR / Cas system protein is catalytically inactive, for example, the catalytically inactive CRISPR / Cas system protein is dCas9. In one embodiment disclosed herein, the CRISPR / Cas system protein is a CRISPR / Cas system protein nickase, such as a Cas9 nickase.In one embodiment disclosed herein, the CRISPR / Cas system protein is thermostable. In one embodiment disclosed herein, the method further comprises amplifying the product of step (b) with a linker-specific PCR. In one embodiment disclosed herein, the method further comprises treating the product of step (b) with an enzyme having exonuclease activity. In one embodiment disclosed herein, the enzyme is exonuclease III or BAL-31. In one embodiment disclosed herein, the method further comprises using a positive control target sequence. In one embodiment disclosed herein, the method further comprises using a negative control gRNA. In one embodiment disclosed herein, the sample is selected from whole blood, plasma, serum, tears, saliva, mucus, cerebrospinal fluid, teeth, bones, nails, feces, urine, tissue and biopsy samples.

[0015] In another aspect, a method for enriching a sample is provided herein, comprising: (a) providing a sample comprising mitochondrial DNA and non-mitochondrial DNA, wherein the mitochondrial DNA and non-mitochondrial DNA are connected by a linker, and wherein the linker is connected to the 5' and 3' ends of the mitochondrial DNA and non-mitochondrial DNA; (b) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to the mitochondrial DNA, thereby producing only a linker connected to the mitochondrial DNA on one end and a linker connected to the non-mitochondrial DNA on both the 5' and 3' ends; and (c) enriching the non-mitochondrial DNA of the sample. In one embodiment disclosed herein, step (c) includes amplifying the product of step (b) with a linker-specific PCR. In one embodiment disclosed herein, step (c) includes treating the product of step (b) with an enzyme having exonuclease activity. In one embodiment disclosed herein, the enzyme is exonuclease III or BAL-31. In one embodiment disclosed herein, the method is performed after a method for analyzing genomic DNA, the method for analyzing genomic DNA comprising treating DNA isolated from a cell population with an insertase to produce a plurality of labeled non-mitochondrial genomic DNA fragments, thereby also generating a residual amount of labeled mitochondrial DNA. In one embodiment disclosed herein, the method further comprises extracting mitochondrial DNA and non-mitochondrial DNA from the sample. In one embodiment disclosed herein, the method further comprises fragmenting the extracted sequences. In one embodiment disclosed herein, mitochondrial DNA is removed by size exclusion. In one embodiment disclosed herein, mitochondrial DNA is removed by using biotin. In one embodiment disclosed herein, enriching the sample comprises amplifying the non-mitochondrial DNA. In one embodiment disclosed herein, the method comprises extracting the non-mitochondrial DNA with at least 10 2A special CRISPR / Cas system protein-gRNA complex is contacted with the sample. In one embodiment disclosed herein, the CRISPR / Cas system protein is Cas9, Cpf1, Cas3, Cas8a-c, Cas10, Cse1, Csy1, Csn2, Cas4, Csm2, or Cm5. In one embodiment disclosed herein, the CRISPR / Cas system protein is Cas9. In one embodiment disclosed herein, the CRISPR / Cas system protein is catalytically inactive, such as dCas9. In one embodiment disclosed herein, the CRISPR / Cas system protein is a CRISPR / Cas system protein nickase, such as a Cas9 nickase. In one embodiment disclosed herein, the CRISPR / Cas system protein is thermostable. In one embodiment disclosed herein, Enrichment includes amplifying the product of step (b) with a linker-specific PCR. In one embodiment disclosed herein, enrichment includes treating the product of step (b) with an enzyme having exonuclease activity. In one embodiment disclosed herein, the enzyme is exonuclease III or BAL-31. In one embodiment disclosed herein, the method further comprises using a positive control target sequence. In one embodiment disclosed herein, the method further comprises using a negative control gRNA. In one embodiment disclosed herein, the sample is selected from whole blood, plasma, serum, tears, saliva, mucus, cerebrospinal fluid, teeth, bones, nails, stool, urine, tissue and biopsy samples.

[0016] In another aspect, the present invention provides a method for enriching a sample, comprising: (a) providing a sample comprising nucleic acids from a first genome and nucleic acids from a second genome, wherein the nucleic acid linker from the first genome is connected to its 5' and 3' ends, and wherein the nucleic acid linker from the second genome is connected to its 5' and 3' ends; (b) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to the target site in the nucleic acid from the first genome, thereby producing nucleic acids from the first genome to which the linker is connected only at one end and nucleic acids from the second genome to which the linker is connected at both the 5' and 3' ends; and (c) enriching the sample for nucleic acids from the second genome. In one embodiment disclosed herein, the sample further comprises nucleic acids from other genomes. In one embodiment disclosed herein, the first genome is a host genome, and the second genome is a non-host genome. In one embodiment disclosed herein, the method comprises using at least 10 2A special CRISPR / Cas system protein-gRNA complex is contacted with a sample. In one embodiment disclosed herein, the nucleic acid is selected from the group consisting of single-stranded DNA, single-stranded RNA, double-stranded DNA, double-stranded RNA, DNA / RNA hybrids, cDNA, synthetic DNA, and artificial DNA. In one embodiment disclosed herein, the nucleic acid is double-stranded DNA. In one embodiment disclosed herein, the nucleic acid is DNA, and the contact of step (b) produces a first genome-DNA and a DNA connector connected to the 5' end instead of the 3' end. The second genome on both the 5' and 3' ends. In one embodiment disclosed herein, the nucleic acid is DNA. In one embodiment disclosed herein, the DNA is genomic DNA. In one embodiment disclosed herein, the CRISPR / Cas system protein is Cas9, Cpf1, Cas3, Cas8a-c, Cas10, Cse1, Csy1, Csn2, Cas4, Csm2, or Cm5. In one embodiment disclosed herein, the CRISPR / Cas system protein is Cas9. In one embodiment disclosed herein, the targeting site in the first genomic nucleic acid is followed by a protospacer sequence adjacent to a motif or (PAM) sequence that can bind to Cas9. In one embodiment disclosed herein, the CRISPR / Cas system protein is catalytically inactive, such as dCas9. In one embodiment disclosed herein, the CRISPR / Cas system protein is a CRISPR / Cas system protein nickase, such as a Cas9 nickase. In one embodiment disclosed herein, the CRISPR / Cas system protein is thermostable. In one embodiment disclosed herein, the first genome is an organism selected from the group consisting of humans, cattle, horses, sheep, pigs, monkeys, dogs, cats, gerbils, birds, mice and rats. In one embodiment disclosed herein, the second genome is from a prokaryotic organism. In one embodiment disclosed herein, the second genome is from a eukaryotic organism. In one embodiment disclosed herein, the second genome is from a parasitic organism. In one embodiment disclosed herein, the second genome is from a virus, a bacterium, a fungus or a protozoan. In one embodiment disclosed herein, the first genomic nucleic acid connected to the linker and the second genomic nucleic acid connected to the linker are 50-1000bp. In one embodiment disclosed herein, the second genomic nucleic acid accounts for less than 50% of the total nucleic acid in the sample. In one embodiment disclosed herein, the second genomic nucleic acid accounts for less than 5% of the total nucleic acid in the sample. In one embodiment disclosed herein, the sample is any one of a biological sample, a clinical sample, a forensic sample, or an environmental sample. In one embodiment disclosed herein, step (c) includes amplifying the product of step (b) with a joint-specific PCR.In one embodiment disclosed herein, step (c) includes treating the product of step (b) with an enzyme having exonuclease activity. In one embodiment disclosed herein, the enzyme is exonuclease III or BAL-31. In one embodiment disclosed herein, step (c) includes removing host nucleic acid by size exclusion. In one embodiment disclosed herein, step (c) includes removing host nucleic acid by using biotin. In one embodiment disclosed herein, the method further includes amplifying the product of step (b) with a linker-specific PCR. In one embodiment disclosed herein, the method further includes treating the product of step (b) with an enzyme having exonuclease activity. In one embodiment disclosed herein, the enzyme is exonuclease III or BAL-31. In one embodiment disclosed herein, the method further includes using a positive control target sequence. In one embodiment disclosed herein, the method further includes using a negative control gRNA. In one embodiment disclosed herein, the sample is selected from whole blood, plasma, serum, tears, saliva, mucus, cerebrospinal fluid, teeth, bones, nails, feces, urine, tissue and biopsy samples.

[0017] In another aspect, the present invention provides a method for enriching a sample, comprising: (a) providing a sample comprising a host nucleic acid and a non-host nucleic acid, wherein the host nucleic acid and the non-host nucleic acid are connected by a linker, and wherein the linker is connected to the 5' and 3' ends of the host nucleic acid and the non-host nucleic acid; (b) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to a target site in the host nucleic acid, thereby generating a host nucleic acid with only a linker connected to one end and a non-host nucleic acid with a linker connected to both the 5' and 3' ends; and (c) enriching the sample for non-host nucleic acids. In one embodiment disclosed herein, the method comprises using at least 10 2A special CRISPR / Cas system protein-gRNA complex is contacted with a sample. In one embodiment disclosed herein, the nucleic acid is selected from the group consisting of single-stranded DNA, single-stranded RNA, double-stranded DNA, double-stranded RNA, DNA / RNA hybrids, cDNA, synthetic DNA, and artificial DNA. In one embodiment disclosed herein, the nucleic acid is double-stranded DNA. In one embodiment disclosed herein, the nucleic acid is DNA, and the contact of step (b) produces a linker connected to a host nucleic acid on the 5' end but not on the 3' end and a linker connected to a non-host nucleic acid on both the 5' and 3' ends. In one embodiment disclosed herein, the nucleic acid is DNA. In one embodiment disclosed herein, the DNA is genomic DNA. In one embodiment disclosed herein, CRISPR / Cas system proteins are Cas9, Cpf1, Cas3, Cas8a-c, Cas10, Cse1, Csy1, Csn2, Cas4, Csm2, or Cm5. In one embodiment disclosed herein, CRISPR / Cas System protein is Cas9. In one embodiment disclosed herein, the targeting site in the first genomic nucleic acid is followed by a protospacer sequence adjacent to a motif or (PAM) sequence that can bind to Cas9. In one embodiment disclosed herein, the CRISPR / Cas system protein is catalytically inactive, such as dCas9. In one embodiment disclosed herein, the CRISPR / Cas system protein is a CRISPR / Cas system protein nickase, such as a Cas9 nickase. In one embodiment disclosed herein, the CRISPR / Cas system protein is thermostable. In one embodiment disclosed herein, the host is selected from the group consisting of humans, cattle, horses, sheep, pigs, monkeys, dogs, cats, gerbils, birds, mice, and rats. In one embodiment disclosed herein, the non-host is a prokaryote. In one embodiment disclosed herein, the non-host is a eukaryote. In one embodiment disclosed herein, the non-host is a parasite. In one embodiment disclosed herein, the non-host is selected from the group consisting of viruses, bacteria, fungi, or protozoa. In one embodiment disclosed herein, the host nucleic acid and the non-host nucleic acid connected by the linker are 50-1000bp. In one embodiment disclosed herein, non-host nucleic acid accounts for less than 50% of the total nucleic acid in the sample. In one embodiment disclosed herein, non-host nucleic acid accounts for less than 5% of the total nucleic acid in the sample. In one embodiment disclosed herein, the sample is any one of a biological sample, a clinical sample, a forensic sample, or an environmental sample. In one embodiment disclosed herein, the sample is any one of a biological sample, a clinical sample, a forensic sample, or an environmental sample. In one embodiment disclosed herein, step (c) includes amplifying the product of step (b) with a joint-specific PCR.In one embodiment disclosed herein, step (c) includes treating the product of step (b) with an enzyme having exonuclease activity. In one embodiment disclosed herein, the enzyme is exonuclease III or BAL-31. In one embodiment disclosed herein, step (c) includes removing host nucleic acid by size exclusion. In one embodiment disclosed herein, step (c) includes removing host nucleic acid by using biotin. In one embodiment disclosed herein, the method also includes amplifying the product of step (b) with a linker-specific PCR. In one embodiment disclosed herein, the method also includes treating the product of step (b) with an enzyme having exonuclease activity. In one embodiment disclosed herein, the enzyme is exonuclease III or BAL-31. In one embodiment disclosed herein, the method also includes using a positive control target sequence. In one embodiment disclosed herein, the method also includes using a negative control gRNA. In one embodiment disclosed herein, the sample is selected from whole blood, plasma, serum, tears, saliva, mucus, cerebrospinal fluid, teeth, bone, nail, feces, urine, tissue and biopsy samples.

[0018] In another aspect, the present invention provides a method for eliminating a targeted sequence in a sample, comprising: (a) providing a sample comprising a sequence of interest and a sequence targeted to be eliminated; (b) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to the targeting sequence, and thereby generating a cleaved targeting sequence; and (c) contacting the product of step (b) with an enzyme having exonuclease activity. In one embodiment disclosed herein, the enzyme is exonuclease III or BAL-31. In one embodiment disclosed herein, the CRISPR / Cas system protein is Cas9. In one embodiment disclosed herein, the sequence targeted to be ablated comprises a sequence encoding a globin, a sequence encoding a transposon, a sequence encoding a retroviral sequence, a sequence comprising a telomeric sequence, a sequence comprising a subtelomeric repeat, a sequence comprising a centromeric sequence, a sequence comprising an intronic sequence, a sequence comprising an Alu repeat, a sequence comprising a SINE repeat, a sequence comprising a LINE repeat, a sequence comprising a dinucleic acid repeat, a sequence comprising a trinucleic acid repeat, a sequence comprising a tetranucleic acid repeat, a sequence comprising a poly A repeat, a sequence comprising a poly T repeat, a sequence comprising a poly C repeat, a sequence comprising a poly G repeat, a sequence comprising an AT-rich sequence, or a sequence comprising a GC-rich sequence. In one embodiment disclosed herein, the method comprises amplifying the nucleotide sequence of at least 10 2A particular CRISPR / Cas system protein-gRNA complex is contacted with a sample. In one embodiment disclosed herein, the CRISPR / Cas system protein is Cas9, Cpf1, Cas3, Cas8a-c, Cas10, Cse1, Csy1, Csn2, Cas4, Csm2, or Cm5. In one embodiment disclosed herein, the sample is selected from whole blood, plasma, serum, tears, saliva, mucus, cerebrospinal fluid, teeth, bones, nails, feces, urine, tissue and biopsy samples.

[0019] In another aspect, the present invention provides a method for producing a cleaved targeting sequence in a sample, comprising: (a) providing a sample comprising a target sequence and a targeting sequence for cleavage; (b) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to the targeting sequence, and thereby producing a cleaved targeting sequence; and (c) separating the CRISPR / Cas system protein from the cleaved targeting sequence; (d) producing other cleaved targeting sequences; and (e) recovering the uncut target sequence. In one embodiment disclosed herein, the CRISPR / Cas system protein is thermostable. In one embodiment disclosed herein, the CRISPR / Cas system protein is thermostable Cas9. In one embodiment disclosed herein, separation of the CRISPR / Cas system protein from the cleaved targeting sequence is accomplished by raising the temperature of the mixture of step (b) to at least 75°C. In one embodiment disclosed herein, producing other cleaved targeting sequences is accomplished by lowering the temperature of the mixture of step (b) to at least 50°C. In one embodiment disclosed herein, step (e) comprises amplifying the product of step (d) with a linker-specific PCR. In one embodiment disclosed herein, step (e) comprises treating the product of step (d) with an enzyme having exonuclease activity. In one embodiment disclosed herein, the enzyme is exonuclease III or BAL-31. In one embodiment disclosed herein, the CRISPR / Cas system protein is Cas9. In one embodiment disclosed herein, the targeting sequence for cutting comprises a sequence encoding a globin, a sequence encoding a transposon, a sequence encoding a retroviral sequence, a sequence comprising a telomeric sequence, a sequence comprising a subtelomeric repeat, a sequence comprising a centromere sequence, a sequence comprising an intronic sequence, a sequence comprising an Alu repeat, a sequence comprising a SINE repeat, a sequence comprising a LINE repeat, a sequence comprising a double nucleic acid repeat, a sequence comprising a three nucleic acid repeat, a sequence comprising a four nucleic acid repeat, a sequence comprising a poly A repeat, a sequence comprising a poly T repeat, a sequence comprising a poly C repeat, a sequence comprising a poly G repeat, a sequence comprising an AT-rich sequence, or a sequence comprising a GC-rich sequence. In one embodiment disclosed herein, the method comprises treating the product of step (d) with at least 10 2 A particular CRISPR / Cas system protein-gRNA complex is contacted with a sample. In one embodiment disclosed herein, the sample is selected from whole blood, plasma, serum, tears, saliva, mucus, cerebrospinal fluid, teeth, bones, nails, feces, urine, tissue and biopsy samples.

[0020] In another aspect, provided herein is a method for eliminating a targeting sequence in a sample, comprising: (a) providing a sample comprising a target sequence and a targeting sequence for cleavage; (b) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to the targeting sequence, thereby generating a cleaved targeting sequence, and wherein the CRISPR / Cas system protein is thermostable; and (c) raising the temperature of the mixture of step (b) to at least 75°C; (d) lowering the temperature of the mixture of step (b) to at least 50°C; (e) repeating steps (c) and (d) at least once; and (f) recovering the uncut target sequence. In one embodiment disclosed herein, step (f) comprises amplifying the product of step (e) with a linker-specific PCR. In one embodiment disclosed herein, step (f) comprises treating the product of step (e) with an enzyme having exonuclease activity. In one embodiment disclosed herein, the enzyme is exonuclease III or BAL-31. In one embodiment disclosed herein, the CRISPR / Cas system protein is Cas9. In one embodiment disclosed herein, the targeting sequence for cleavage comprises a sequence encoding a globin, a sequence encoding a transposon, a sequence encoding a retroviral sequence, a sequence comprising a telomeric sequence, a sequence comprising a subtelomeric repeat, a sequence comprising a centromere sequence, a sequence comprising an intronic sequence, a sequence comprising an Alu repeat, a sequence comprising a SINE repeat, a sequence comprising a LINE repeat, a sequence comprising a dinucleic acid repeat, a sequence comprising a trinucleic acid repeat, a sequence comprising a tetranucleic acid repeat, a sequence comprising a poly A repeat, a sequence comprising a poly T repeat, a sequence comprising a poly C repeat, a sequence comprising a poly G repeat, a sequence comprising an AT-rich sequence, or a sequence comprising a GC-rich sequence. In one embodiment disclosed herein, the method comprises using at least 10 2 A specific CRISPR / Cas system protein-gRNA complex is contacted with a sample. In one embodiment disclosed herein, the sample is selected from: whole blood, plasma, serum, tears, saliva, mucus, cerebrospinal fluid, teeth, bones, nails, feces, urine, tissue and biopsy samples.

[0021] In another aspect, provided herein is a method for sequentially depleting a targeted nucleic acid in a sample, comprising: (a) providing a sample comprising host nucleic acid and non-host nucleic acid, wherein the non-host nucleic acid comprises nucleic acid from at least one known non-host organism and nucleic acid from at least one unknown non-host organism; (b) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is configured to hybridize with a targeting sequence in the host nucleic acid, thereby cleaving a portion of the host nucleic acid; (c) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is configured to hybridize with a targeting sequence in at least one known non-host nucleic acid, thereby cleaving a portion of the at least one known non-host nucleic acid; and (d) isolating the nucleic acid from the unknown non-host organism. In one embodiment disclosed herein, the method comprises using at least 10 2 A particular CRISPR / Cas system protein-gRNA complex is contacted with the sample, wherein the CRISPR / Cas system protein-gRNA complex is configured to hybridize with a target sequence in a host nucleic acid. The method comprises using at least 10 2 A particular CRISPR / Cas system protein-gRNA complex is contacted with a sample, and the CRISPR / Cas system protein-gRNA complex is configured to hybridize with a targeting sequence in at least one known non-host nucleic acid. In one embodiment disclosed herein, the sample is selected from: whole blood, plasma, serum, tears, saliva, mucus, cerebrospinal fluid, teeth, bones, nails, feces, urine, tissue and biopsy samples. In one embodiment disclosed herein, the nucleic acid from the unknown non-host organism accounts for less than 5% of the total nucleic acid in the sample. In one embodiment disclosed herein, the host is a human. In one embodiment disclosed herein, the at least one known non-host organism is a species of Streptococcus.

[0022] In another aspect, the present invention provides a method for analyzing genomic DNA, comprising: (a) treating DNA of a cell population isolated from a sample with an insertional enzyme to produce a plurality of labeled non-mitochondrial genomic DNA fragments, thereby also producing a residual amount of labeled mitochondrial DNA; (b) enriching the non-mitochondrial DNA in the product of step (a) according to any relevant method provided herein. For example, such a method for enriching a sample can include: (a) providing a sample comprising mitochondrial DNA and non-mitochondrial DNA, wherein the mitochondrial DNA and the non-mitochondrial DNA are adapter-connected, and wherein the adapter is connected to the 5' and 3' ends of the mitochondrial DNA and the non-mitochondrial DNA; (b) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to the mitochondrial DNA, thereby producing only mitochondrial DNA with an adapter connected to one end and non-mitochondrial DNA with an adapter connected to both the 5' and 3' ends; and (c) enriching the sample for non-mitochondrial DNA. In one embodiment disclosed herein, the method further comprises (a) sequencing at least a portion of the tagged fragments to generate a plurality of sequence reads; and (b) preparing an epigenetic map of a region of the cell genome by mapping information obtained from the sequence reads to the region. In one embodiment disclosed herein, the sample is selected from whole blood, plasma, serum, tears, saliva, mucus, cerebrospinal fluid, teeth, bones, nails, stool, urine, tissue and biopsy samples.

[0023] In another aspect, provided herein is a composition comprising a mixture of DNA from a first genome and DNA from a second genome, wherein the first genomic DNA and the second genomic DNA are connected by a linker, and wherein the first genomic DNA is complexed with a gRNA-CRISPR / Cas system protein complex. In one embodiment disclosed herein, the first genome is from a host organism and the second genome is from a non-host organism. In one embodiment disclosed herein, the CRISPR / Cas system protein is Cas9. In any embodiment disclosed herein, the CRISPR / Cas system protein is thermostable.

[0024] In another aspect, a kit is provided herein. In another aspect, a kit comprising: (a) a CRISPR / Cas system protein; and (b) a gRNA, wherein the gRNA is complementary to mitochondrial DNA. In another aspect, a kit comprising: (a) a CRISPR / Cas system protein; (b) a gRNA, wherein the gRNA is complementary to a target of interest; and (c) an enzyme having exonuclease activity is provided herein. In another aspect, a kit comprising: (a) a CRISPR / Cas system protein, wherein the CRISPR / Cas system protein is thermostable; and (b) a gRNA, wherein the gRNA is complementary to a target of interest. In another aspect, a kit comprising: (a) a CRISPR / Cas system protein; (b) a first gRNA group, wherein the gRNA is complementary to a target sequence of interest, and (c) a control reagent group is provided herein. In another aspect, provided herein is a kit comprising: (a) a reagent for isolating DNA from a cell population; (b) an insertion enzyme; (c) a CRISPR / Cas system protein; and (d) a plurality of gRNAs, wherein the gRNA is complementary to mitochondrial DNA. In any of the kits disclosed herein, the kit further comprises a collection of Y-type linkers or a collection of poly-G linkers. In any of the kits disclosed herein, the CRISPR / Cas system protein is Cas9. In any of the kits disclosed herein, the kit further comprises a positive control reagent group, for example, a positive control reagent group comprises a collection of nucleic acid fragments, wherein the fragments comprise a target sequence of interest, and the gRNA is at least 85% complementary to the target sequence of interest. In any of the kits disclosed herein, the kit further comprises a negative control reagent group, for example, a negative control reagent group comprises a second gRNA group, wherein the second gRNA group exhibits reduced binding to the target sequence of interest compared to the first gRNA group; or, for example, a negative control group reagent group may comprise a collection of nucleic acid fragments, wherein the fragments are no more than 90% complementary to the first gRNA group. In any of the kits disclosed herein, the kit further comprises at least 10 2 A special gRNA.

[0025] On the other hand, the present invention provides a method for eliminating a targeted sequence in a sample, comprising: providing a sample comprising a target sequence and a sequence targeted to be eliminated; and contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to the targeting sequence, thereby generating a cut targeting sequence. In a related aspect, the present invention provides a method for eliminating one of the targeted sequences in a sample, comprising: providing a nucleic acid extracted from a sample, wherein the extracted nucleic acid sequence comprises a target sequence and a targeting sequence for one of elimination and segmentation; providing a plurality of guide RNA (gRNA)-CRISPR / Cas system protein complexes, wherein the gRNA is configured to hybridize with different targeting sequences; mixing the nucleic acid with the gRNA-CRISPR / Cas system protein complex, wherein at least a portion of the plurality of gRNA-CRISPR / Cas system protein complexes hybridizes with the targeting sequence. In one embodiment disclosed herein, the method further comprises extracting a nucleic acid sequence from the sample. In one embodiment disclosed herein, the CRISPR / Cas system protein is Cas9. In one embodiment disclosed herein, the method further comprises fragmenting the extracted nucleic acid. In one embodiment disclosed herein, the method further comprises connecting the 5' and 3' end adapters of the fragmented extracted sequence. In one embodiment disclosed herein, the method further comprises incubating the mixture to cut the targeting sequence. In one embodiment disclosed herein, each sequence targeted to be eliminated is followed by a protospacer sequence adjacent to a motif or (PAM) sequence that can bind to a Cas9 protein derived from a bacterial species, but wherein the target sequence (to be enriched) is not targeted by the gRNA. In one embodiment disclosed herein, the Cas9 protein comprises a catalytically inactive Cas9, which includes an affinity tag previously attached thereto, further comprising dividing the mixture into a first part and a second part, the first part comprising a complementary target-specific nucleic acid sequence, which is present in a mixture comprising a guide RNA / Cas9 complex, and the second part comprising a fragmented extracted nucleic acid sequence that is not bound to the guide RNA / Cas9 complex, wherein the segmentation is performed with an affinity tag. In one embodiment disclosed herein, the cut extracted nucleic acid sequence is smaller than the uncut fragmented extracted nucleic acid sequence, and the method further comprises removing the cut extracted nucleic acid sequence from the mixture by size selective exclusion. In one embodiment disclosed herein, the method further comprises amplifying the extracted nucleic acid sequence of the fragmentation that is not cut. In one embodiment disclosed herein, the method further comprises analyzing each of the first and second parts by amplification and sequencing. In one embodiment disclosed herein, the sample is any one of a biological sample, a clinical sample, a forensic sample, or an environmental sample.In one embodiment disclosed herein, the extracted nucleic acid comprises a host nucleic acid sequence and a non-host nucleic acid sequence. In one embodiment disclosed herein, the non-host nucleic acid sequence comprises a microbial nucleic acid sequence. In one embodiment disclosed herein, the microbial nucleic acid sequence comprises any one of a bacterial, a viral, and a eukaryotic parasitic nucleic acid sequence. In one embodiment disclosed herein, at least a portion of the host nucleic acid sequence is contained in a targeting sequence for one of reduction or segmentation. In one embodiment disclosed herein, all host nucleic acid sequences are substantially contained in a targeting sequence for one of reduction or segmentation. In one embodiment disclosed herein, the extracted nucleic acid comprises a plurality of different ribosomal RNA sequences and a plurality of different target-specific gRNAs comprise at least a portion of a target nucleic acid sequence, and the target nucleic acid sequence is configured to hybridize with a portion of the plurality of different ribosomal RNA sequences. In one embodiment disclosed herein, the extracted nucleic acid sequence comprises a plurality of different mitochondrial nucleic acid sequences and a plurality of different target-specific gRNAs comprise one or more target nucleic acid sequences, and the target nucleic acid sequence is configured to hybridize with a portion of a plurality of different mitochondrial nucleic acid sequences. In one embodiment disclosed herein, the extracted nucleic acid sequence comprises a plurality of different repetitive nucleic acid sequences in the targeted nucleic acid sequence to be eliminated and a plurality of different target-specific gRNAs comprises at least one target nucleic acid sequence that can hybridize with a portion of the plurality of different repetitive nucleic acid sequences. In one embodiment disclosed herein, the extracted nucleic acid comprises any one of single-stranded DNA, double-stranded DNA, single-stranded RNA, double-stranded RNA, cDNA, synthetic DNA, artificial DNA, and DNA / RNA hybrids. In one embodiment disclosed herein, the target sequence accounts for less than 50% of the extracted nucleic acid. In one embodiment disclosed herein, the target sequence accounts for less than 5% of the extracted nucleic acid.

[0026] In another aspect, the present invention provides a guide RNA library comprising a plurality of target-specific guide RNAs, each of which is configured to hybridize with a selected target nucleic acid sequence, wherein each guide RNA comprises a sequence that can bind to a Cas9 protein. In one embodiment disclosed herein, each selected target nucleic acid sequence is followed by a protospacer sequence adjacent to a motif. In one embodiment disclosed herein, the target-specific gRNA comprises a gRNA suitable for hybridizing with a selected target nucleic acid sequence in a human genome. In one embodiment disclosed herein, the human genome comprises a nucleic acid sequence comprising a plurality of different repetitive nucleic acid sequences, and the target-specific gRNA comprises a suitable guiding element for hybridizing with each of the plurality of different repetitive nucleic acid sequences.

[0027] In another aspect, the technology disclosed herein relates to methods and systems for selectively or targeted depletion and / or selectively or targeted fragmentation of nucleic acid samples using Cas9-enzyme mediated methods.

[0028] In another aspect, the technology disclosed herein relates to forming a library of gRNAs, wherein each gRNA is suitable for hybridizing with a nucleic acid sequence targeted for removal from a total nucleic acid sample, wherein the targeted sequence is followed by a protospacer adjacent motif (PAM) sequence. By mixing the gRNA with a nucleic acid sample and a Cas9 protein derived from a bacterial species, the gRNA hybridizes with the nucleic acid sequence targeted to be removed, and the Cas9 enzyme forms a guide RNA / Cas9 complex that binds to the nucleic acid sequence targeted to be removed. Subsequently, the guide RNA / Cas9 complex can be incubated to cut the targeted nucleic acid sequence, thereby separating the cut sequence from the uncut nucleic acid sequence, or so that the targeted sequence bound to the guide RNA / Cas9 complex can be separated from the DNA sequence that is not bound to the guide RNA / Cas9 complex.

[0029] In another aspect, the technology disclosed herein can also be used to deplete host molecules from nucleic acid samples containing low levels (e.g., <50%) of non-host nucleic acids.

[0030] In another aspect, the technology disclosed herein includes: 1) combining a genomic DNA sample or a sequencing library with a mixture of a Cas9-gRNA complex, wherein the Cas9-gRNA complex comprises a Cas9 protein and a Cas9-related gRNA complementary to a predefined site in the genome; and b) incubating the reaction mixture to cut only the target region. In embodiments where the sequencing library is targeted, Cas9 cutting separates two sequencing adapters, thereby making these fragments unable to be amplified. In embodiments where genomic DNA is targeted, Cas9 cutting makes these fragments small enough to be removed by size selection. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 A general schematic diagram of the subtractive approach using Cas9 to selectively cleave target sequences in a library is shown.

[0033] Figure 2 A general schematic diagram of the subtractive approach using catalytically inactive Cas9 to partition a library into target and non-target sequences is shown.

[0034] Figure 3 An exemplary strategy for subtracting mitochondrial DNA from a sequencing library, leaving only non-mitochondrial DNA for sequencing, is shown.

[0035] Figure 4Shown are the results of a depletion experiment where mitochondrial DNA was depleted by approximately 44% (measured by qPCR).

[0036] Figure 5 Shown are the results of a second experiment in which a higher amount of guide RNA was used and mitochondrial DNA was depleted by about 70% (measured by qPCR).

[0037] Fig. 6A Shown are the results of sequencing libraries before and after mitochondrial DNA subtraction. Figure 6B Shown is the subtraction of mitochondrial DNA using different amounts of gRNA.

[0038] Figure 7 Cas9 nickase-mediated DNA depletion is shown.

[0039] Figure 8 Cas9-mediated excision followed by exonuclease III treatment is shown.

[0040] Fig. 9 Cas9-mediated excision followed by exonuclease Bal-31 treatment is shown.

[0041] Fig.10 Showing biotin labeling during Cas-9-mediated excision

[0042] Fig.11 The use of thermostable Cas9 is shown to increase the efficiency of Cas9-mediated depletion. DETAILED DESCRIPTION OF THE INVENTION

[0044] definition

[0045] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described.

[0046] The section headings provided herein are not limitations of the various aspects or embodiments of the invention. Accordingly, the terms defined below are more fully defined by reference to the specification as a whole.

[0047] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Singleton et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 2D ED., John Wiley and Sons, New York (1994) and Hale & Markham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, NY (1991) provide a general meaning for many of the terms used herein to those of skill in the art. However, for the purpose of clarity and ease of reference, some terms are defined below.

[0048] Numeric ranges are inclusive of the numbers defining the range.

[0049] As used herein, the term "sample" refers to a material or mixture of materials, typically but not necessarily in liquid form, which contains one or more analytes of interest.

[0050] The term "nucleic acid sample" as used herein refers to a sample containing nucleic acids. As used herein, a nucleic acid sample may be complex in that it contains multiple different molecules containing sequences. Genomic DNA from mammals (e.g., mouse or human) is a type of complex sample. A complex sample may have more than 10 4 , 10 5 , 10 6 or 10 7 Different nucleic acid molecules. The DNA target can be derived from any source, such as genomic DNA, cDNA or artificial DNA constructs. Any sample containing nucleic acids, such as genomic DNA made from tissue culture cells or tissue samples can be used in this article.

[0051] The term "nucleotide" is intended to include those parts containing not only known purine and pyrimidine bases, but also modified other heterocyclic bases. Such modifications include methylated purines or pyrimidines, acylated purines or pyrimidines, alkylated ribose or other heterocycles. In addition, the term "nucleotide" includes those parts containing haptens or fluorescent labels, and it may contain not only conventional ribose and deoxyribose sugars, but also other sugars. Modified nucleosides or nucleotides also include modifications to the sugar moiety, for example, wherein one or more hydroxyl groups are replaced by halogen atoms or aliphatic groups, or are functionalized as ethers, amines, etc.

[0052] The terms "nucleic acid" and "polynucleotide" are used interchangeably herein. Polynucleotides are used to describe nucleic acid polymers of any length, such as greater than about 2 bases, greater than about 10 bases, greater than about 100 bases, greater than about 500 bases, greater than 1000 bases, up to about 10,000 or more bases, which are composed of nucleotides, such as deoxyribonucleotides or ribonucleotides, and can be produced enzymatically or synthetically (e.g., PNA described in U.S. Patent No. 5,948,902 and references cited therein), which can hybridize in a sequence-specific manner similar to two naturally occurring nucleic acids, such as can participate in Watson-Crick base pairing interactions. Naturally occurring nucleotides include guanine, cytosine, adenine and thymine (G, C, A and T, respectively). DNA and RNA have deoxyribose and ribose backbones, respectively, while the backbone of PNA consists of repeated N-(2-aminoethyl)-glycine units connected by peptide bonds. In PNA, various purine and pyrimidine bases are connected to the backbone by methylene carbonyl bonds. Locked nucleic acid (LNA), often referred to as inaccessible RNA, is a modified RNA nucleotide. The ribose moiety of the LNA nucleotide is modified by an additional bridge connecting 2' oxygen and 4' carbon. The bridge "locks" the ribose in the 3' inner (North) conformation (3'-endo (North) conformation), usually in the form of an A-type duplex. Once desired, LNA nucleotides can be mixed with DNA or RNA residues in oligonucleotides. The term "unstructured nucleic acid" or "UNA" is a nucleic acid containing non-natural nucleotides that are bound to each other with reduced stability. For example, an unstructured nucleic acid can contain G' residues and C' residues, wherein these residues correspond to non-naturally occurring forms (i.e., analogs) of G and C, which base pair with each other with reduced stability, but retain the ability to base pair with naturally occurring C and G residues, respectively. Unstructured nucleic acids are described in US20050233340, which is incorporated herein by reference for disclosure of UNA.

[0053] The term "oligonucleotide" as used herein refers to a single-stranded polymer of nucleotides.

[0054] Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.

[0055] The term "cleavage" as used herein refers to a reaction that breaks the phosphodiester bond between two adjacent nucleotides in both strands of a double-stranded DNA molecule, thereby resulting in a double-strand break in the DNA molecule.

[0056] As used herein, the term "cleavage site" refers to a site at which a double-stranded DNA molecule has been cleaved.

[0057] The term "hybridization" refers to the process known in the art of binding of a nucleic acid strand to a complementary strand by base pairing. A nucleic acid is considered to "selectively hybridize" to a reference nucleic acid sequence if the two sequences specifically hybridize to each other under medium to high stringency hybridization and washing conditions. Medium and high stringency hybridization conditions are known (see, e.g., Ausubel et al., Short Protocols in Molecular Biology, 3rd Edition, Wiley & Sons 1995 and Sambrook et al., Molecular Cloning: A Laboratory Manual, Third Edition, 2001 Cold Spring Harbor, NY). An example of high stringency conditions includes hybridization at about 42°C in 50% formamide, 5X SSC, 5X Denhardt's solution, 0.5% SDS, and 100 μg / m denatured carrier DNA, followed by washing twice in 2X SSC and 0.5% SDS at room temperature, and washing twice more in 0.1×SSC and 0.5% SDS at 42°C.

[0058] As used herein, the term "duplex" or "double-stranded" describes two complementary polynucleotides that are base paired, ie, hybridized together.

[0059] As used herein, the term "amplifying" refers to producing one or more copies of a target nucleic acid using a target nucleic acid as a template.

[0060] The term "depletion" with respect to a genome refers to the removal of a portion of a genome from the rest of the genome to produce a product that is isolated from the rest of the genome. The term "depletion" also encompasses the removal of DNA from one species while retaining DNA from another species.

[0061] The term "genomic region" as used herein refers to a region of a genome, such as an animal or plant genome, such as a human, monkey, rat, fish, or insect or plant genome. In some cases, a reference genomic region, i.e., a genomic region of known nucleotide sequence, such as a chromosome region whose sequence is deposited in the Genbank database of NCBI or other databases, can be used to design the oligonucleotides used in the methods described herein.

[0062] The term "genomic sequence" used herein refers to a sequence present in a genome. Because RNA is transcribed from a genome, the term encompasses sequences present in the nuclear genome of an organism, as well as sequences present in cDNA copies of RNA (e.g., mRNA) transcribed from the genome.

[0063] As used herein, the term "genomic fragment" refers to a region of a genome, such as an animal or plant genome, such as a human, monkey, rat, fish or insect or plant genome. A genomic fragment can be a whole chromosome or a fragment of a chromosome. A genomic fragment can be adapter-connected (in which case it has an adapter connected to one or both ends of the fragment or to at least the 5' end of the molecule), or it may not be adapter-connected.

[0064] In some cases, the oligonucleotides used in the methods described herein can be designed with reference genomic regions, i.e., genomic regions of known nucleotide sequences, such as chromosome regions whose sequences are deposited in the Genbank database of NCBI or other databases. Such oligonucleotides can be used in assays using samples containing test genomes, wherein the test genomes contain binding sites for the oligonucleotides.

[0065] As used herein, the term "ligating" refers to the enzymatic joining of the terminal nucleotide at the 5' end of a first DNA molecule to the terminal nucleotide at the 3' end of a second DNA molecule.

[0066] If two nucleic acids are "complementary", each base in one of the nucleic acids pairs with the corresponding nucleotide base in the other nucleic acid. The terms "complementary" and "fully complementary" are used synonymously herein.

[0067] As used herein, the term "separating" refers to the physical separation of two elements (eg, by size or affinity, etc.) as well as the degradation of one element, leaving the other element intact.

[0068] In cells, DNA is usually present in double-stranded form, therefore has two complementary nucleic acid chains, referred to herein as "top" and "bottom" chains. In some cases, the complementary chains of chromosome regions can be referred to as "positive" and "negative" chains, "first" and "second" chains, "coding" and "non-coding" chains, "Watson" and "Crick" chains or "justice" and "antisense" chains. It is arbitrary that the chain is assigned as top or bottom chain, and does not mean any specific orientation, function or structure. The first and second chains are different molecules until they are covalently linked. For ease of description, the "top" and "bottom" chains of the double-stranded nucleic acid to which the top and bottom chains are covalently linked will still be described as "top" and "bottom" chains. In other words, for the purpose of the present invention, the top and bottom chains of double-stranded DNA do not need to be separated molecules. The nucleotide sequence of the first chain of several exemplary mammal chromosome regions (such as BAC, assemblies, chromosomes, etc.) is known, and can be found in the Genbank database of NCBI, for example.

[0069] As used herein, the term "top strand" refers to either strand of a nucleic acid, but not both strands of a nucleic acid. When an oligonucleotide or primer binds or anneals only to the top strand, it binds only to one strand and not to the other. As used herein, the term "bottom strand" refers to the strand complementary to the "top strand." When an oligonucleotide binds or anneals "only one strand," it binds only to one strand, such as the first or second strand, but not the other strand. If an oligonucleotide binds or anneals to both strands of a double-stranded DNA, the oligonucleotide may have two regions, a first region that hybridizes to the top strand of the double-stranded DNA and a second region that hybridizes to the bottom strand of the double-stranded DNA.

[0070] The term "double-stranded DNA molecule" refers to a double-stranded DNA molecule in which the top and bottom strands are not covalently linked as well as a double-stranded DNA molecule in which the top and bottom strands are covalently linked. The top and bottom strands of the double-stranded DNA base pair with each other through Watson-Crick interaction.

[0071] The term "denaturation" as used herein refers to separating at least a portion of the base pairs of a nucleic acid duplex by placing the duplex under suitable denaturing conditions. Denaturing conditions are well known in the art. In one embodiment, in order to denature a nucleic acid duplex, the duplex can be exposed to a temperature higher than the Tm of the duplex, thereby releasing one strand of the duplex from the other. In some embodiments, the nucleic acid can be denatured by exposing it to a temperature of at least 90°C for an appropriate time (e.g., at least 30 seconds, up to 30 minutes). In some embodiments, complete denaturing conditions can be used to completely separate the base pairs of the duplex. In other embodiments, partial denaturing conditions (e.g., using a lower temperature than complete denaturing conditions) can be used to separate the base pairs of certain parts of the duplex (e.g., regions rich in AT base pairs can be separated, and regions rich in GC base pairs can remain paired). Chemical denaturation (e.g., using urea or NaOH) can also be performed on the nucleic acid.

[0072] As used herein, the term "genotyping" refers to any type of analysis of nucleic acid sequences and includes sequencing, polymorphism (SNP) analysis, and analysis to identify rearrangements.

[0073] The term "sequencing" as used herein refers to a method of obtaining the identity of consecutive nucleotides of a polynucleotide.

[0074] The term "next generation sequencing" refers to so-called parallel sequencing-by-synthesis or sequencing-by-ligation platforms, such as those currently used by Illumina, Life Technologies, and Roche, etc. Next generation sequencing methods may also include nanopore sequencing methods or methods based on electronic detection, such as the Ion Torrent technology commercialized by Life Technologies.

[0075] The term "host nucleic acid" refers to nucleic acids derived from a multicellular eukaryotic subject from which a sample is obtained. The host nucleic acid can be, for example, a plant or an animal, including a mammal, particularly a human. The term "host nucleic acid" includes nuclear nucleic acids as well as nucleic acids present in other organelles, such as mitochondria and chloroplasts (if the host is a plant), rather than nucleic acids of microorganisms that are typically grown in or on a subject.

[0076] The term "non-host nucleic acid" refers to nucleic acid that does not belong to the host from which the sample was obtained. Non-host nucleic acid can be viral, bacterial or other microbial DNA.

[0077] The term "microbial nucleic acid" refers to nucleic acid of a microbial origin (eg, bacteria or virus or from a eukaryotic parasite) that is present in a sample.

[0078] The term "host DNA" refers to DNA derived from a multicellular eukaryotic subject from which the sample is obtained. The host DNA can be, for example, a plant or an animal, including a mammal, particularly a human. The term "host DNA" includes nuclear DNA as well as DNA present in other organelles, such as mitochondria and chloroplasts (if the host is a plant), rather than DNA of microorganisms that normally grow in or on the subject.

[0079] The term "non-host DNA" refers to DNA that does not belong to the host from which the sample was obtained. Non-host DNA can be viral, bacterial or other microbial DNA.

[0080] The term "microbial DNA" refers to genomic DNA of a microorganism of origin (eg, bacteria or virus or from a eukaryotic parasite) present in a sample.

[0081] The term "complementary DNA" or cDNA refers to a double-stranded DNA sample generated from an RNA sample by reverse transcription of the RNA (using primers such as random hexamers or oligo-dT primers) followed by second strand synthesis by RNase H digestion of the RNA and synthesis with a DNA polymerase.

[0082] The term "RNA promoter linker" refers to a linker containing a promoter of bacteriophage RNA polymerase (eg, RNA polymerase from bacteriophage T3, T7, SP6, etc.).

[0083] The term "metagenomic sample" refers to a sample containing more than one organism (eukaryotic, prokaryotic or viral).

[0084] The term "metagenomic analysis" refers to the analysis of metagenomic samples.

[0085] Additional definitions for terms may appear throughout the specification.

[0086] Purpose of the Invention

[0087] In view of the problems associated with the above-mentioned conventional methods and apparatuses, an object of the present invention is to deplete selected nucleic acids from a nucleic acid sample using an enzyme-mediated cleavage mechanism.

[0088] Another object of the present invention is to provide a method for subtracting selected host nucleic acids from a sequencing library comprising host and non-host nucleic acids to increase the proportion of non-host nucleic acid fragments for the purpose of pursuing downstream applications, including but not limited to amplification, sequencing, cloning, etc.

[0089] Another object of the present invention is to provide a metagenomic analysis method that is unbiased with respect to fragments of the genome from a specific species by selectively subtracting some or all of the genomes of the specific species from a metagenomic sample.

[0090] Another object of the present invention is to obtain better resolution in metagenomic analysis by increasing the number of sample reads mapped to the metagenome of a species without increasing (or even decreasing, in some cases) the sequencing amount.

[0091] Another object of the present invention is to provide methods and compositions for subtracting mitochondrial DNA from a sample containing both mitochondrial DNA and non-mitochondrial DNA.

[0092] Nucleic acid, sample

[0093] The nucleic acids of the invention (targeted for enrichment, depletion or depletion) can be single-stranded DNA, single-stranded RNA, double-stranded DNA, double-stranded RNA, artificial DNA, artificial RNA, synthetic DNA, synthetic RNA and RNA / DNA hybrids.

[0094] Nucleic acid of the present invention can be a genomic fragment comprising a genomic region or the entire genome itself. In one embodiment, the genome is a DNA genome. In another embodiment, the genome is an RNA genome.

[0095] The nucleic acids of the invention can be obtained from eukaryotic or prokaryotic organisms; from mammalian or non-mammalian organisms; from animals or plants; from bacteria or viruses; from animal parasites; or from pathogens.

[0096] The nucleic acids of the present invention can be obtained from any mammalian organism. In one embodiment, the mammal is a human. In another embodiment, the mammal is a livestock animal, such as a horse, sheep, cow, pig or donkey. In another embodiment, the mammalian organism is a domestic pet, such as a cat, dog, gerbil, mouse, rat. In another embodiment, the mammal is a type of monkey.

[0097] The nucleic acids of the present invention may be obtained from any bird or avian organism. Avian organisms include, but are not limited to, chickens, turkeys, ducks and geese.

[0098] The nucleic acid of the present invention can be obtained from a plant. In one embodiment, the plant is rice, corn, wheat, rose, grape, coffee bean, fruit, tomato, potato or cotton.

[0099] In some embodiments, the nucleic acids of the invention are obtained from bacterial species. In one embodiment, the bacteria are bacteria that cause tuberculosis.

[0100] In some embodiments, nucleic acids of the invention are obtained from viruses.

[0101] In some embodiments, nucleic acids of the invention are obtained from fungal species.

[0102] In some embodiments, nucleic acids of the invention are obtained from algal species.

[0103] In some embodiments, nucleic acids of the invention are obtained from any mammalian parasite.

[0104] In some embodiments, the nucleic acids of the invention are obtained from any mammalian parasite. In one embodiment, the parasite is a helminth. In another embodiment, the parasite is a parasite that causes malaria. In another embodiment, the parasite is a parasite that causes leishmaniasis. In another embodiment, the parasite is an amoeba.

[0105] In one embodiment, the nucleic acids of the present invention include nucleic acids that are gRNA targets (also referred to herein as gRNA elements interchangeable) and nucleic acids that are not gRNA targets in the same sample.

[0106] In one embodiment, the nucleic acids in the sample include a target nucleic acid / targeting sequence (the target of the gRNA) and a nucleic acid / target sequence of interest (not targeted by the gRNA).

[0107] In one embodiment, nucleic acids all belong to the same organism, but the targeted subset is used for elimination or segmentation. For example, nucleic acids with little information value can be targeted. Examples of nucleic acids with little information value include, but are not limited to: mitochondrial DNA, mitochondrial RNA, mitochondrial rRNA, repetitive sequences, multicopy sequences, sequences encoding globin, sequences encoding transposons, sequences encoding retroviral sequences, sequences comprising telomeric sequences, sequences comprising subtelomeric repetitions, sequences comprising centromere sequences, sequences comprising intronic sequences, sequences comprising Alu repetitions, SINE repetitions, LINE repetitions, double nucleic acid repetitions, three nucleic acid repetitions, four nucleic acid repetitions, poly A repetitions, poly T repetitions, poly C repetitions, poly G repetitions, sequences rich in AT or sequences rich in GC.

[0108] In one embodiment, the sample is contacted with a CRISPR / Cas system protein-gRNA complex, wherein the gRNA is complementary to the following sequence: a target sequence to be subtracted, a target sequence encoding a globin, a sequence encoding a transposon, a sequence encoding a retroviral sequence, a sequence comprising a telomeric sequence, a sequence comprising a subtelomeric repeat, a sequence comprising a centromere sequence, a sequence comprising an intronic sequence, a sequence comprising an Alu repeat, a sequence comprising a SINE repeat, a sequence comprising a LINE repeat, a sequence comprising a dinucleic acid repeat, a sequence comprising a trinucleic acid repeat, a sequence comprising a tetranucleic acid repeat, a sequence comprising poly A repeats, a sequence comprising poly T repeats, a sequence comprising poly C repeats, a sequence comprising poly G repeats, a sequence comprising an AT-rich sequence, or a sequence comprising a GC-rich sequence.

[0109] In one exemplary embodiment, ribosomal RNA can be targeted for subtraction or segmentation. In another exemplary embodiment, repetitive DNA can be targeted for subtraction or segmentation. In such an embodiment, the method can be used to subtract ribosomal or repetitive DNA or any other DNA that has little information value in order to reduce the sequencing cost of these elements of DNA extraction and increase data output / yield.

[0110] In one embodiment, the target DNA can be non-mitochondrial DNA (eg, genomic DNA) and the DNA of interest can be mitochondrial DNA, and mitochondrial DNA is enriched by targeting and depleting non-mitochondrial human DNA.

[0111] In one embodiment, the target DNA to be eliminated can be mitochondrial DNA, and the target DNA can be non-mitochondrial DNA, and the non-mitochondrial DNA is enriched by targeting and eliminating mitochondrial human DNA. In an exemplary embodiment, the ATAC-Seq procedure (e.g., see WO2014 / 189957) is implemented to produce unwanted residual mitochondrial DNA; the method of the present invention can be used to remove unwanted mitochondrial DNA from a sample.

[0112] In one embodiment, the nucleic acid to be subtracted or split may be a non-mapped region of the genome; and the nucleic acid to be retained for further analysis / sequencing / cloning may be a mappable region of the genome. In one embodiment, the nucleic acid to be subtracted or split may be a mappable region of the genome; and the nucleic acid to be retained for further analysis / sequencing / cloning may be a non-mapped region of the genome. Examples of non-mapped regions include telomeres, centromeres, repeat regions, or other genomic regions that contain difficult-to-map features.

[0113] In some embodiments, the method of the present invention is carried out on a sample comprising a host nucleic acid and a non-host nucleic acid. In one embodiment, the host nucleic acid is mammalian, and the non-host nucleic acid is not mammalian (e.g., bacteria, viruses, fungi, protozoa). In one embodiment, the host nucleic acid is human, and the non-host nucleic acid is bacterial. In one embodiment, the host nucleic acid is human, and the non-host nucleic acid is viral. In one embodiment, the host nucleic acid is human, and the non-host nucleic acid is fungal. In one embodiment, the host nucleic acid is human, and the non-host nucleic acid is protozoa. In one embodiment, the host nucleic acid is from a kind of livestock. In one embodiment, the host nucleic acid is from monkeys. In a specific embodiment, the host nucleic acid is human, and the non-host nucleic acid is from unidentified pathogens, such as known or unknown viruses, or known or unknown bacteria, or known or unknown animal parasites. In a specific embodiment, the host nucleic acid is from cattle, and the non-host nucleic acid is viral, bacteria, fungi or protozoa.

[0114] In a sample containing both host and non-host nucleic acids, the host and non-host may have, for example, a host-pathogen relationship or a symbiotic relationship. In some embodiments, the non-host portion of the total nucleic acid sample obtained from the host may be derived from a microbial population associated with the host.

[0115] In one embodiment, the sample obtained from a host organism (e.g., a human host) contains nucleic acids from more than one non-host organism, such as from multiple non-host organisms, comprising at least one unknown non-host organism to be identified. The compositions and methods of the present invention can be used to continuously process nucleic acids in a sample, to first subtract / segment the host DNA, and then to subtract / segment other known non-host nucleic acids of non-purpose, with the remaining representing a non-host nucleic acid pool of a specific purpose. For example, such an embodiment may be applicable to the following situation, in which the host is expected to carry more than one known bacteria, such as bacteria that exist in a symbiotic manner. For example, such an embodiment may be applicable to detecting unknown pathogens in saliva samples from individuals, and it is known that saliva contains several bacteria, such as Streptococcus species. In another example, the sample may be a fecal sample from a mammalian host, including known and unknown non-host nucleic acids.

[0116] In one embodiment, a sample obtained from a known host organism (e.g., a human host) contains non-host nucleic acids, but the non-host is unknown (e.g., an unknown pathogenic bacteria, virus, or other pathogen in human blood) until the host nucleic acids are depleted or fragmented, thereby enriching for non-host nucleic acids and performing further downstream analysis.

[0117] In an exemplary embodiment, when the DNA includes host DNA and non-host DNA, the method can be used to eliminate substantially all of the host DNA to construct a non-host DNA library for further analysis. In the case where the DNA includes nuclear DNA and mitochondrial DNA, the method can be used to eliminate mitochondrial DNA to construct a nuclear DNA library for further analysis; or eliminate nuclear DNA to construct a mitochondrial DNA library for further analysis. In the case where the DNA includes an abundant sequence of ribosomal RNA or repetitive DNA that may have little information value, the method can be used to eliminate ribosomal or repetitive DNA or any other DNA that has little information value in order to reduce the sequencing cost of these elements extracted from the DNA and improve the data yield. In each application, the resulting DNA has significantly less DNA fragments to sequence, thereby reducing sequencing costs and complexity. In addition, according to the method of the present invention, the sample that is eliminated still provides all DNA materials that are not actively eliminated that are present in the biological sample, which provides the following advantages: reducing sequencing costs, and improving data output / yield by sequencing smaller DNA samples with lower diversity.

[0118] In one embodiment, nucleic acid of the present invention is obtained from biological sample. Biological sample for obtaining nucleic acid includes but is not limited to whole blood, plasma, serum, tears, saliva, mucus, cerebrospinal fluid, teeth, bones, nails, feces, urine, tissue, tissue biopsy sample etc. Biological sample can include forensic sample, such as tooth, bone, nail etc. Biological sample can include tissue, tissue biopsy sample, such as excised lung tissue. Biological sample can include clinical sample, it refers to the sample obtained in clinical environment (such as in hospital or clinic).

[0119] In one embodiment, the nucleic acid of the invention is obtained from an environmental sample, for example, from water, soil, air or rock.

[0120] In one embodiment, nucleic acids of the invention are obtained from a forensic sample, e.g., a sample obtained from an individual at a crime scene, obtained from evidence, an autopsy, as part of an ongoing investigation, and the like.

[0121] In one embodiment, the nucleic acids of the invention are provided in a library.

[0122] Nucleic acid of the present invention is provided or extracted from a sample. Extraction can extract substantially all nucleic acid sequences from a sample. It can be, for example, the nucleic acid sequence of a host present in the sample and the nucleic acid sequence of any non-human or non-host organism.

[0123] Extraction can produce host nucleic acid and non-host nucleic acid in any ratio between 99.999:0.001 and 0.001:99.999. Extraction can produce targeted nucleic acid and target nucleic acid in any ratio between 99.999:0.001 and 0.001:99.999. Extraction can produce nucleic acid to be subtracted: nucleic acid to be retained / analyzed / sequenced in any ratio between 99.999:0.001 and 0.001:99.999. Extraction can produce nucleic acid to be segmented: nucleic acid to be retained / analyzed / sequenced in any ratio between 99.999:0.001 and 0.001:99.999. Extraction from a biological sample can produce host nucleic acid to be subtracted: nucleic acid from more than one non-host to be retained / analyzed / sequenced in any ratio between 99.999:0.001 and 0.001:99.999. In these embodiments, the ratio can be equal to or fall anywhere between 99.999:0.001 and 0.001:99.999, for example, the ratio can be 99:1, 95:5, 90:10, 85:15, 80:20, 75:25, 70:30, 65:35, 60:40, 55:45, 50:50, 45:55, 40:60, 35:65, 30:70, 25:75, 20:80, 15:85, 10:90, 5:95, and 1:99.

[0124] After extraction, the extracted nucleic acid sequences can be fragmented to reduce the length of each extracted nucleic acid to a more manageable length for amplification, sequencing, etc.

[0125] As provided herein, at least 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90% of the starting nucleic acid material can be reduced or split. Such reduction or segmentation can be achieved in no more than 10 minutes, 15 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes, 120 minutes, 150 minutes, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours or 12 hours.

[0126] In one embodiment, nucleic acid of the present invention is connected by a joint. The scope of nucleic acid of the present invention to be connected by a joint can be 10bp to 1000bp. For example, the nucleic acid to be connected by a joint can be at least 10, 15, 20, 25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950 or 1000bp. In a specific embodiment, the nucleic acid to be connected by a joint is 100bp. In a specific embodiment, the nucleic acid to be connected by a joint is 200bp. In a specific embodiment, the nucleic acid to be connected by a joint is 300bp. In a specific embodiment, the nucleic acid to be connected by a joint is 400bp. In a specific embodiment, the nucleic acid to be connected by a joint is 500bp.

[0127] In some embodiments, the sample comprises a library of nucleic acid fragments, wherein the nucleic acid fragments are connected with joints at their 5' and 3' ends. In such embodiments, joints are connected to each end of each nucleic acid fragment at the 5' and 3' ends. In other embodiments, joints can be connected to only one end of each fragment. In some embodiments, joints also include an intervening sequence between the 5' end and / or the 3' end. For example, joints can also include a barcode sequence.

[0128] In some embodiments, an adaptor is a nucleic acid that can be ligated to both strands of a double-stranded DNA molecule.

[0129] In some embodiments, the adapter is connected before subtraction / enrichment. In other embodiments, the adapter is connected in a subsequent step.

[0130] In some embodiments, the linker is linear. In some embodiments, the linker is linear Y-shaped. In some embodiments, the linker is linear circular. In some embodiments, the linker is a hairpin linker.

[0131] In various embodiments, the linker can be a hairpin linker, ie, a molecule that base pairs with itself to form a double-stranded stem and loop structure, wherein the 3' and 5' ends of the molecule are attached to the 5' and 3' ends of the double-stranded DNA molecule of the fragment, respectively.

[0132] Alternatively, the adapter can be a Y-adapter, also referred to as a universal adapter, connected to one or both ends of the fragment. Alternatively, the adapter itself can be composed of two different oligonucleotide molecules that are base paired with each other. In addition, the ligatable end of the adapter can be designed to be compatible with the overhang made by restriction endonuclease cleavage, or it can have a blunt end or a 5' T overhang.

[0133] The linker can include double-stranded and single-stranded molecules. Therefore, the linker can be DNA or RNA, or a mixture of the two. Linkers containing RNA can be cut by RNase treatment or alkaline hydrolysis.

[0134] The length of the joint can be 10 to 100 bp, but without departing from the present invention, joints outside this range can be used. In a specific embodiment, the length of the joint is at least 10 bp, at least 15 bp, at least 20 bp, at least 25 bp, at least 30 bp, at least 35 bp, at least 40 bp, at least 45 bp, at least 50 bp, at least 55 bp, at least 60 bp, at least 65 bp, at least 70 bp, at least 75 bp, at least 80 bp, at least 85 bp, at least 90 bp, or at least 95 bp.

[0135] In some cases, joint can comprise the oligonucleotide of the nucleotide sequence that is designed to match host genome specific region, for example its sequence is deposited in the chromosome region of the Genbank database of NCBI or other database.This type of oligonucleotide can be used for the mensuration of the sample that uses to contain test genome, wherein test genome contains the binding site of oligonucleotide.In other examples, can derive the nucleotide sequence of fragmentation from one or more DNA sequencing libraries.Can configure joint for next generation sequencing platform, for example, for Illumina sequencing platform or for IonTorrents platform, or use together with Nanopore technology.

[0136] Guide RNA

[0137] Provided herein are guide RNAs (gRNAs), wherein the gRNAs are complementary to (or, can hybridize with) a targeting site or targeting sequence in a nucleic acid (e.g., in genomic DNA from a host). In one embodiment, the invention provides a guide RNA library comprising a collection of gRNAs configured to hybridize with a nucleic acid sequence targeted for ablation or segmentation.

[0138] In one embodiment, the gRNA is selective for a target nucleic acid (or targeting sequence) in a sample, but is not selective for a sequence of interest in the sample.

[0139] In one embodiment, gRNA is selective for host nucleic acid in biological sample from host, but not selective for non-host nucleic acid in sample from host. In one embodiment, gRNA is selective for non-host nucleic acid in biological sample from host, but not selective for host nucleic acid in sample. In one embodiment, gRNA is selective for subset of host nucleic acid and non-host nucleic acid in biological sample from host. For example, if complex biological sample comprises host nucleic acid and nucleic acid from more than one non-host organism, then the gRNA can be selective for more than one non-host species. In such an embodiment, gRNA is used for continuous elimination or segmentation of non-target sequence. For example, saliva from people contains human DNA, and DNA of more than one bacterial strain, but may also contain genomic material of unknown pathogenic organism. In such an embodiment, gRNA pointing to human DNA and known bacteria can be used to continuously eliminate human DNA and DNA of known bacteria, so as to obtain a sample containing genomic material of unknown pathogenic organism.

[0140] In an exemplary embodiment, the gRNA is selective for human host DNA obtained from a biological sample from the host, but does not hybridize to DNA of an unknown organism (eg, a pathogen) in the sample.

[0141] In some embodiments, the gRNA is selective for a target nucleic acid sequence, followed by a protospacer sequence adjacent to a motif (PAM) sequence that can bind to Cas9. In some embodiments, the sequence of the gRNA is determined by the type of CRISPR / Cas system protein. For example, in various embodiments, the gRNA can be customized for different Cas9 types because the PAM sequence can vary depending on the type of bacteria from which the Cas9 is derived.

[0142] The size range of gRNA can be, for example, 50-250 base pairs. For example, gRNA can be at least 50bp, 55bp, 60bp, 65bp, 70bp, 75bp, 80bp, 85bp, 90bp, 95bp, 100bp, 110bp, 120bp, 125bp, 130bp, 140bp, 150bp, 160bp, 170bp, 175bp, 180bp, 190bp, or 195bp. In a specific embodiment, gRNA is 80bp, 90bp, 100bp or 110bp. Each target-specific gRNA comprises a base pair sequence complementary to a predefined site in the target nucleic acid, followed by a protospacer sequence adjacent to a motif or (PAM) sequence that can bind to a CRISPR / Cas system protein (e.g., a Cas9 protein derived from a bacterial species). In specific embodiments, the base pair sequence of the gRNA that is complementary to a predetermined site in the target nucleic acid is 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 base pairs.

[0143] The present invention also provides a gRNA library. The gRNA library can include a plurality of different species-specific gRNAs, each of which is configured to hybridize (selectively) with a nucleic acid sequence targeted for elimination or segmentation. Each gRNA includes a target-specific guide sequence and a stem-loop binding site, which is formed to bind to a specific CRISPR / Cas system protein, such as Cas9 protein. The library can include a plurality of different guide RNAs, each of which has a different 15 to 20 base pair sequence, which is complementary to different predefined sites in the targeted nucleic acid, followed by an appropriate PAM sequence that can bind to the CRISPR / Cas system protein. For each guide RNA, the PAM sequence is present in the predefined DNA target sequence of the target nucleic acid, but is not present in the corresponding target-specific guide sequence.

[0144] Generally according to the present invention, any nucleic acid sequence in the genome of interest having a predefined target sequence and a subsequent appropriate PAM sequence can be hybridized with the corresponding guide RNA provided in the guide RNA library and bound to a CRISPR / Cas system protein (e.g., Cas9). In various embodiments, the gRNA library can be customized for different CRISPR / Cas system proteins, such as different Cas9 types, because the PAM sequence can vary depending on the species of bacteria producing the protein.

[0145] Different target-specific sequences in gRNA can be generated. This can be achieved by using a promoter of a bacteriophage RNA polymerase (e.g., RNA polymerase from bacteriophage T3, T7, SP6, etc.). Therefore, Each different T7 RNA polymerase promoter provides a different target-specific sequence suitable for hybridizing with different target nucleic acid sequences. A non-limiting exemplary set of forward primers that can be used for both annealing and subsequent PCR reactions are listed in Table 1 and Table 2 of Example 1 provided below.

[0146] Without being limited to theory, if the gRNAs show ~100% efficacy, the distance between gRNAs that achieve >95% target nucleic acid cleavage can be calculated: This can be calculated by measuring the distribution of library sizes and determining the mean, N and standard deviation SD; N-2SD = minimum size for >95% of the library to ensure that there is one guide RNA for each fragment of that size to ensure >95% reduction. This can also be described as the maximum distance between guide RNAs = mean of library size - 2×(standard deviation of library size).

[0147] In the embodiments provided herein, the gRNA library can be expanded to include a large number of copies of each different gRNA, and a large number of different gRNAs that may be suitable for the desired subtraction results. The number of unique gRNAs in a given guide RNA library in the human genome can range from 1 particular gRNA to as many as 10. 10 In some embodiments, the library comprises at least 10 2 In some embodiments, the library comprises at least 10 2 , at least 10 3 , at least 10 4 , at least 10 5 , at least 10 6 , at least 10 7 , at least 10 8 , at least 10 9 , at least 10 10 In one exemplary embodiment, the library comprises about 10 3 A special gRNA.

[0148] In embodiments provided herein, the method comprises contacting a sample comprising nucleic acid with a plurality of CRISPR / Cas9 system protein-gRNA complexes, wherein the gRNA is complementary to a target sequence that is targeted for excision. In some embodiments, the method comprises using a gRNA that can base pair with a target site, wherein the sample is contacted with at least 102 In some embodiments, the sample is contacted with at least 10 2 , at least 10 3 , at least 10 4 , at least 10 5 , at least 10 6 , at least 10 7 , at least 10 8 , at least 10 9 , at least 10 10 In one exemplary embodiment, the sample is contacted with about 10 3 A specific gRNA contact.

[0149] In embodiments provided herein, the method comprises exposing the sample to at least 10 2 The method comprises contacting a sample with at least 10 2 In some embodiments, the sample is contacted with at least 10 2 , at least 10 3 , at least 10 4 , at least 10 5 , at least 10 6 , at least 10 7 , at least 10 8 , at least 10 9 , at least 10 10 In one exemplary embodiment, the sample is contacted with about 10 3 A specific CRISPR / Cas system protein-gRNA complex contacts.

[0150] In the embodiments provided herein, the method comprises contacting a sample comprising genomic DNA with a plurality of CRISPR / Cas9 system protein-gRNA complexes, wherein the gRNA is complementary to a targeted site in the genome to be ablated. In some embodiments, the method comprises using a gRNA that can be base-paired with a targeted DNA, wherein the target site of interest is at least every 1 bp, at least every 2 bp, at least every 3 bp, at least every 4 bp, at least every 5 bp, at least every 6 bp, at least every 7 bp, at least every 8 bp, at least every 9 bp, at least every 10 bp, at least every 11 bp, at least every 12 bp, at least every 13 bp, at least every 14 bp, at least every 15 bp, at least every 16 bp, at least every 17 bp, at least every 18 bp, at least every 19 bp, 20 bp, at least every 25 bp, at least every 30 bp, at least every 40 bp, at least every 50 bp, at least every 100 bp, at least every 200 bp, at least every 300 bp, at least every 400 bp, at least every 500 bp, At least every 600bp, at least every 700bp, at least every 800bp, at least every 900bp, at least every 1000bp, at least every 2500bp, at least every 5000bp, at least every 10,000bp, at least every 15,000bp, at least every 20,000bp, at least every 25,000bp, at least every 50,000bp, at least every 100,000bp, at least every 250,000bp, at least every 500,000bp, at least every 750,000bp, or even at least every 1,000,000bp.

[0151] In the embodiments provided herein, the method includes contacting a sample containing a nucleic acid targeted to be eliminated with a plurality of CRISPR / Cas9 system protein-gRNA complexes, wherein the gRNA is complementary to the nucleic acid targeted to be eliminated. In some embodiments, the molar ratio of gRNA: nucleic acid targeted to be eliminated is 1: 1, 5: 1, 10: 1, 50: 1, 100: 1, 150: 1, 250: 1, 500: 1, 750: 1, 1000: 1, 1500: 1, 2000: 1, 2500: 1, 5000: 1, 7500: 1, or even 10,000: 1. In an exemplary embodiment, the molar ratio of gRNA: nucleic acid targeted to be eliminated is 500: 1.

[0152] In the embodiments provided herein, the method includes contacting a sample containing a nucleic acid targeted to be eliminated with a plurality of CRISPR / Cas9 system protein-gRNA complexes, wherein the gRNA is complementary to the nucleic acid targeted to be eliminated. In some embodiments, the weight ratio of gRNA: nucleic acid targeted to be eliminated is 1: 1, 5: 1, 10: 1, 20: 1, 30: 1, 40: 1, 50: 1, 60: 1, 70: 1, 80: 1, 90: 1, 100: 1, 150: 1, 250: 1, 500: 1, 750: 1, 1000: 1, 1500: 1, 2000: 1, 2500: 1, 5000: 1, 7500: 1, or even 10,000: 1. In an exemplary embodiment, the weight ratio of gRNA: nucleic acid targeted to be eliminated is 50: 1 to 100: 1.

[0153] The following description is for reference Figure 1 As an exemplary embodiment. Figure 1 In the method, the guide RNA library (1050) contains a large number of different human-specific gRNAs (1055), each of which is configured to hybridize with a human DNA or nucleic acid sequence from a collection of DNA extracted fragments (1025) or other fragments that can be eliminated (because it is not of interest), and the human DNA or nucleic acid sequence is targeted for elimination. In this embodiment, the nucleic acid sequence targeted to be eliminated is not a sequence present in the non-human genetic fragment (1030) of interest for further analysis. Each guide RNA (1055) includes a target-specific guide sequence (1060) and a stem-loop binding site (1065) formed to bind to the Cas9 protein. Each target-specific guide sequence (1060) is a 15 to 20 base pair sequence complementary to a predefined site in the human genome, followed by a protospacer sequence adjacent to a motif or (PAM) sequence that can bind to a Cas9 protein derived from a bacterial species. Other available base pair lengths can range from about 8 to 100 base pairs without departing from the present invention.

[0154] exist Figure 1 In the present invention, different target-specific sequences (1060) are generated by different T7 RNA polymerase promoter sequences (1070) containing promoters of bacteriophage RNA polymerases (e.g., RNA polymerases from bacteriophages T3, T7, SP6, etc.). Thus, each different T7 RNA polymerase promoter (1070) provides a different target-specific sequence (1060) suitable for hybridizing with different human DNA sequences.

[0155] exist Figure 1In some embodiments, amplifying the guide RNA library (1050) to include a large number of copies of each different gRNA (1055) and a large number of different gRNAs, such as (1055a)(1055b)(1055n) may be appropriate to obtain the desired subtraction results.

[0156] CRISPR / Cas system proteins

[0157] Provided herein are compositions and methods for eliminating unwanted nucleic acids in a sample, and / or enriching a sequence of interest in a sample. These compositions and methods utilize CRISPR / Cas system proteins.

[0158] In some embodiments, the CRISPR / Cas system proteins include proteins from a CRISPR type I system, a CRISPR type II system, and a CRISPR type III system.

[0159] In some embodiments, CRISPR / Cas system proteins can be from any bacterial or archaeal species.

[0160] In some embodiments, the CRIPR / Cas system protein is from or is derived from a CRIPR / Cas system protein from the following species / genus: Streptococcus pyogenes, Staphylococcus aureus, Neisseria meningitidis, Streptococcus thermophiles, Treponema denticola, Francisella tularensis, Pasteurella multocida, Campylobacter jejuni, Campylobacter lari, Mycoplasma gallisepticum, Nitratifractor salsuginis, Parvibaculum lavamentivorans), Roseburia intestinalis, Neisseria cinerea, Gluconacetobacter diazotrophicus, Azospirillum, Sphaerochaetaglobus, Flavobacterium columnare, Fluviicolataffensis, Bacteroides coprophilus, Mycoplasmamobile, Lactobacillus farciminis, Streptococcus pasteurianus, Lactobacillus johnsonii, Staphylococcus pseudintermedius, Filifactor alocis, Legionella pneumophila, Suterella wadsworthensis), or Corynebacter diphtheria.

[0161] In some embodiments, examples of CRISPR / Cas system proteins may be naturally occurring or engineered.

[0162] In some embodiments, naturally occurring CRISPR / Cas system proteins include Cas9, Cpf1, Cas3, Cas8a-c, Cas10, Cse1, Csy1, Csn2, Cas4, Csm2 and Cm5. In an exemplary embodiment, the CRISPR / Cas system protein includes Cas9.

[0163] "CRISPR / Cas system protein-gRNA complex" refers to a complex comprising a CRISPR / Cas system protein and a guide RNA, which can be composed of two molecules, namely an RNA ("crRNA"), which hybridizes with the target and provides sequence specificity, and an RNA, namely "tracrRNA", which can hybridize with the crRNA. Alternatively, the guide RNA can be a single molecule (ie, gRNA) containing crRNA and tracrRNA sequences. The CRISPR / Cas system protein can be at least 60% identical to the wild-type CRISPR / Cas system protein (e.g., at least 70%, at least 80%, or 90% identical, at least 95% identical or at least 98% identical or at least 99% identical). The CRISPR / Cas system protein can have all the functions of the wild-type CRISPR / Cas system protein, or only one or some functions, including binding activity, nuclease activity, and nuclease activity.

[0164] The term "guide RNA associated with a CRISPR / Cas system protein" refers to a guide RNA as described above (comprising a crRNA molecule and a tracrRNA molecule, or a single RNA molecule comprising crRNA and tracrRNA sequences). The guide RNA associated with a CRISPR / Cas system protein can exist as an isolated RNA, or as part of a CRISPR / Cas system protein-gRNA complex.

[0165] Cas9

[0166] In some embodiments, the CRISPR / Cas system protein comprises Cas9. The Cas9 of the present invention can be isolated, recombinantly produced or synthesized.

[0167] Cas9 proteins that can be used in embodiments herein can be found at http: / / www.nature.com / nature / journal / v520 / n7546 / full / nature14299.html.

[0168] In some embodiments, Cas9 is a type II CRISPR system derived from Streptococcus pyogenes, Staphylococcus aureus, Neisseria meningitidis, Streptococcus thermophilus, Treponema denticola, Francisella tularensis, Pasteurella multocida, Campylobacter jejuni, Campylobacter seagulls, Mycoplasma gallisepticum, Nitrate-lysing Bacterium bitterns, Corynebacterium parvum, Roseburia intestinalis, Neisseria griseus, Gluconobacter diazotrophicus, Azospirillum, Sphaerochaeta globus, Flavobacterium columnaris, Trichoderma taffyci, Bacteroides coprophilum, Mycoplasma motilium, Lactobacillus fargesii, Streptococcus pasteurianus, Lactobacillus johnsonii, Staphylococcus pseudintermedius, Gingivalis sulci, Legionella pneumophila, Sutterella waldensis, or Corynebacterium diphtheriae.

[0169] In some embodiments, Cas9 is a type II CRISPR system derived from Streptococcus pyogenes, and the PAM sequence is NGG located at the immediate 3' end of the target-specific guide sequence. PAM sequences of type II CRISPR systems from exemplary bacterial species may also include: Streptococcus pyogenes (NGG), Staphylococcus aureus (NNGRRT), Neisseria meningitidis (NNNNGA TT), Streptococcus thermophilus (NNAGAA) and Treponema denticola (NAAAAC), which can all be used without departing from the present invention. ((http: / / www.nature.com / nature / journal / v520 / n7546 / full / nature14299.html)).

[0170] In an exemplary embodiment, the Cas9 sequence can be obtained, for example, from the pX330 plasmid (available from Addgene), re-amplified by PCR, and then cloned into pET30 (from EMD Biosciences) to express and purify the recombinant 6His-tagged protein in bacteria.

[0171] "Cas9-gRNA complex" refers to a complex comprising a Cas9 protein and a guide RNA. The guide RNA can be composed of two molecules, namely an RNA ("crRNA") that hybridizes with the target and provides sequence specificity, and an RNA that can hybridize with the crRNA, namely "tracrRNA". Alternatively, the guide RNA can be a single molecule (i.e., gRNA) containing crRNA and tracrRNA sequences. The Cas9 protein can be at least 60% identical to the wild-type Cas9 protein (e.g., at least 70%, at least 80%, or 90% identical, at least 95% identical or at least 98% identical or at least 99% identical) with the wild-type Cas9 protein (e.g., with the Streptococcus pyogenes Cas9 protein). The Cas9 protein can have all the functions of the wild-type Cas9 protein, or only one or some functions, including binding activity, nuclease activity, and nuclease activity.

[0172] The term "Cas9-associated guide RNA" refers to a guide RNA as described above (comprising a crRNA molecule and a tracrRNA molecule, or comprising an RNA molecule containing crRNA and tracrRNA sequences). The Cas9-associated guide RNA can exist as an isolated RNA or as part of a Cas9-gRNA complex.

[0173] Catalytically inactive CRISPR / Cas system proteins

[0174] In some embodiments, the engineering examples of CRISPR / Cas system proteins include catalytically inactive CRISPR / Cas system proteins. The term "catalytically inactive" generally refers to CRISPR / Cas system proteins with inactivated HNH and RuvC nucleases. Such proteins can bind to target sites in any nucleic acid (wherein the target site is determined by the guide RNA), but the protein cannot cut or nick double-stranded DNA.

[0175] In some embodiments, the catalytically inactive CRISPR / Cas system protein is dCas9, dCpf1, dCas3, dCas8a-c, dCas10, dCse1, dCsy1, dCsn2, dCas4, dCsm2, or dCm5.

[0176] In one embodiment, the catalytically inactive CRISPR / Cas system protein is dCas9. Thus, dCas9 allows for the partitioning of the mixture into unbound nucleic acid and dCas9-bound fragments that are targeted for partitioning. In one embodiment, the dCas9 / gRNA complex binds to a target determined by the gRNA sequence. The bound dCas9 can prevent cleavage by Cas9, while other operations proceed. This Figure 2In one embodiment, the dCas9 / gRNA complex binds to a target determined by the gRNA sequence, and the bound portion of the target nucleic acid sample can be removed by an affinity tag (e.g., biotin) previously attached to the dCas9 protein. The bound nucleic acid sequence can be eluted from the dCas9 / gRNA complex by denaturing conditions and then amplified and sequenced. Conversely, in another embodiment, those nucleic acids targeted by dCas9 can be discarded, and the remaining nucleic acids can be analyzed by amplification and sequencing.

[0177] CRISPR / Cas system protein nickase

[0178] In some embodiments, the engineered embodiments of CRISPR / Cas system proteins also include Cas nickases. Cas nickases refer to a modified version of CRISPR / Cas system proteins that contains a single inactive catalytic domain.

[0179] In some embodiments, the CRISPR / Cas system protein nickase is a Cas9 nickase, a Cpf1 nickase, a Cas3 nickase, a Cas8a-c nickase, a Cas10 nickase, a Cse1 nickase, a Csy1 nickase, a Csn2 nickase, a Cas4 nickase, a Csm2 nickase, or a Cm5 nickase.

[0180] In one embodiment, the CRISPR / Cas system protein nickase is a Cas9 nickase.

[0181] In some embodiments, the Cas9 nickase can be used to bind to a target sequence. The term "Cas9 nickase" refers to a modified version of the Cas9 protein that contains a single inactive catalytic domain, such as a RuvC- or HNH domain. With only one active nuclease domain, the Cas9 nickase only cuts one target DNA strand, producing a single-strand break or "gap". Depending on which mutant is used, the strand hybridized with the guide RNA or the non-hybridized strand can be cut. The Cas9 nickase bound to two gRNAs targeting opposite strands can produce double-strand breaks in DNA. This "double nickase" strategy increases the specificity of the cut because it requires the Cas9 / gRNA complex to specifically bind to the site before forming a double-strand break.

[0182] In an exemplary embodiment, the reduction of DNA can be performed using a Cas9 nickase. In one embodiment, the method includes: preparing a DNA sequencing library containing DNA to be removed (e.g., non-target human DNA) and target DNA (e.g., DNA from an unknown pathogen); designing a guide RNA so that all DNA to be reduced has two adjacent (e.g., less than 15 bases apart) guide RNA binding sites on the opposite DNA strand; adding the Cas9 nickase and the guide RNA to the DNA library. In this embodiment, the Cas9 nickase recognizes its target site on the DNA to be removed and only cuts one strand. For the DNA to be reduced, two independent Cas9 nickases can cut both strands of the DNA to be removed (e.g., human DNA); only the DNA to be removed (e.g., human DNA) will have two adjacent Cas9 nickase sites, which produce double-strand breaks. If the Cas9 nickase recognizes a site on the target DNA (e.g., pathogenic DNA) non-specifically or with low affinity, only one strand is cut that will not prevent subsequent PCR amplification or downstream processing of the DNA molecule. This diagram is shown in Figure 7 In this embodiment, the chance of two guide RNAs non-specifically recognizing two adjacent sites is negligible (<1×10-14). This embodiment is particularly useful if conventional Cas9-mediated cleavage cuts off too much target DNA.

[0183] Dissociable and thermostable CRISPR / Cas system proteins

[0184] Although CRISPR / Cas system proteins can be used in conjunction with guide RNA libraries to efficiently deplete a pool of target DNA, large amounts (e.g., >30 pmoles) of CRISPR / Cas system proteins and guide RNAs may be required. One reason for the typically >100-fold excess of target DNA is that, unlike classical restriction enzymes (e.g., EcoRI) that completely dissociate from their target DNA after cleavage, CRISPR / Cas system proteins do not completely recycle after the cleavage reaction is complete. CRISPR / Cas system proteins, such as Cas9, may remain bound to one of the two daughter DNA product molecules (see Fig.11 , open circles on the left). Therefore, it may be necessary to provide more CRISPR / Cas system proteins and gRNA to achieve complete elimination of unwanted DNA.

[0185] In some embodiments, to overcome this problem, a dissociable CRISPR / Cas system protein is provided herein. For example, when cutting a targeting sequence, the CRISPR / Cas system protein can be dissociated from the gRNA or the target. In some embodiments, dissociation is induced by increasing the reaction temperature. This can work by increasing the processivity of the enzyme by compounding it with an available gRNA, re-associating with another target sequence, and producing another cut target sequence.

[0186] In some embodiments, to overcome this problem, a thermostable CRISPR / Cas system protein is provided herein. In such an embodiment, the reaction temperature is increased, causing the dissociation of the protein; the reaction temperature is reduced, allowing the generation of additional cleaved target sequences. In some embodiments, when maintained at least at 75°C for at least 1 minute, the thermostable CRISPR / Cas system protein maintains at least 50% activity, at least 55% activity, at least 60% activity, at least 65% activity, at least 70% activity, at least 75% activity, at least 80% activity, at least 85% activity, at least 90% activity, at least 95% activity, at least 96% activity, at least 97% activity, at least 98% activity, at least 99% activity or 100% activity. In some embodiments, the thermostable CRISPR / Cas system protein maintains at least 50% activity when maintained at least 75°C, at least 80°C, at least 85°C, at least 90°C, at least 91°C, at least 92°C, at least 93°C, at least 94°C, at least 95°C, 96°C, at least 97°C, at least 98°C, at least 99°C, or at least 100°C for at least 1 minute. In some embodiments, the thermostable CRISPR / Cas system protein maintains at least 50% activity when maintained at least 75°C for at least 1 minute, 2 minutes, 3 minutes, 4 minutes, or 5 minutes. In some embodiments, the thermostable CRISPR / Cas system protein maintains at least 50% activity when the temperature is increased and reduced to 25°C-50°C. In some embodiments, the temperature is reduced to 25°C, to 30°C, to 35°C, to 40°C, to 45°C, or to 50°C. In an exemplary embodiment, the thermostable enzyme retains at least 90% of its activity after 1 minute at 95°C.

[0187] In some embodiments, the thermostable CRISPR / Cas system protein is a thermostable Cas9, a thermostable Cpf1, a thermostable Cas3, a thermostable Cas8a-c, a thermostable Cas10, a thermostable Cse1, a thermostable Csy1, a thermostable Csn2, a thermostable Cas4, a thermostable Csm2, or a thermostable Cm5.

[0188] In some embodiments, the thermostable CRISPR / Cas system protein is a thermostable Cas9.

[0189] In an exemplary embodiment, a thermostable Cas9 complexed with a guide RNA (e.g., a gRNA library targeting human DNA) can be applied to a sequencing library of a DNA mixture (containing, for example, 95% human DNA and 5% viral DNA). Fig.11 As shown (gray circles on the right), after allowing Cas9 to digest for a period of time, the temperature of the sample mixture can be increased, for example, up to 95°C or higher, which can cause DNA denaturation and dissociation of gRNA and Cas9 from the DNA target. The binding of Cas9 to gRNA can be increased so that Cas9-gRNA dissociates from the DNA target as a complete complex despite DNA denaturation. Dimethyl sulfoxide can be added to reduce the temperature required for DNA denaturation so that the Cas9 protein structure is not affected. Cas9 preferentially binds to uncleaved target sites, and thermostable Cas9 can retain activity after boiling. Due to these characteristics, by increasing the temperature, for example, up to 100°C, and cooling the reaction to, for example, 37°C, thermostable Cas9 can remain able to bind to its gRNA and cut more of its substrate. By allowing the recovery of Cas9, the efficiency of elimination can be improved, and the probability of off-target (non-specific) cutting can also be reduced as less Cas9 is required in the reaction.

[0190] Thermostable CRISPR / Cas system proteins can be isolated, for example, by identifying sequence homology in the genomes of thermophilic bacteria Streptococcus thermophilus and Pyrococcus furiosus. The CRISPR / Cas system genes can then be cloned into expression vectors. In an exemplary embodiment, a thermostable Cas9 protein is isolated.

[0191] In another embodiment, a thermostable CRISPR / Cas system protein can be obtained by in vitro evolution of a non-thermostable CRISPR / Cas system protein. The sequence of the CRISPR / Cas system protein can be mutated to improve its thermostability. In some embodiments, this can be achieved by site-directed mutagenesis to remove excess loop sequences, increase the number of ionic bridges between protein domains, or generate a potential mutant library by dilution into droplets and PCR. In an exemplary embodiment, a thermostable Cas9 is generated by in vitro evolution of a non-thermostable Cas9.

[0192] Inventive method

[0193] Enrichment of target sequence / elimination of target sequence

[0194] Provided herein are methods for enriching a sample for a sequence of interest by depleting non-target sequences (a target sequence is a sequence that is targeted to be eliminated).

[0195] In one embodiment, a method for enriching a sample for a target sequence comprises:

[0196] Providing a sample comprising a sequence of interest and a sequence targeted for elimination, wherein the sequence of interest accounts for less than 50%, less than 45%, less than 40%, less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1%, less than 0.05%, less than 0.01%, less than 0.005%, or even less than 0.001% of the sample; contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to the targeting sequence, thereby cleaving the targeting sequence. In an exemplary embodiment, the CRISPR / Cas system protein is Cas9.

[0197] In one embodiment, a method for enriching a sample of non-mitochondrial DNA includes: (a) providing a sample comprising mitochondrial DNA and non-mitochondrial DNA, wherein the mitochondrial DNA and the non-mitochondrial DNA are connected by a linker, and wherein the linker is connected to the 5' and 3' ends of the mitochondrial DNA and the non-mitochondrial DNA; (b) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to the mitochondrial DNA, thereby producing a mitochondrial DNA with only a linker connected to one end, and a non-mitochondrial DNA with a linker connected to both the 5' and 3' ends; and (c) enriching the non-mitochondrial DNA of the sample. In some embodiments, the sample is enriched with a linker-specific PCR. In some embodiments, enrichment includes treating the product of step (b) with an enzyme having exonuclease activity, such as exonuclease III or BAL-31. For example, if exonuclease III is used, the linker can be Y-shaped. If BAL-31 is used, the linker can include a poly-G tail. In some embodiments, the sample is enriched by purifying the sequence of interest.

[0198] In another embodiment, the method of enriching a sample comprises: (a) providing a sample comprising nucleic acid from a first genome and nucleic acid from a second genome, wherein a nucleic acid adapter from the first genome is connected to its 5' and 3' ends and wherein a nucleic acid adapter from the second genome is connected to its 5' and 3' ends; (b) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to a site on a nucleic acid from the first genome, thereby producing a nucleic acid from the first genome with only an adapter connected to one end and a nucleic acid from the second genome with an adapter connected to both the 5' and 3' ends; and (c) enriching the sample for nucleic acid from the first genome. In some embodiments, the sample is enriched with adapter-specific PCR. In some embodiments, enrichment comprises treating the product of step (b) with an enzyme having exonuclease activity, such as exonuclease III or BAL-31. For example, if exonuclease III is used, the adapter can be Y-shaped. If BAL-31 is used, the adapter can include a poly-G tail. In some embodiments, the sample is enriched by purifying the sequence of interest.

[0199] In another embodiment, a method for enriching a sample for non-host nucleic acids comprises: providing a sample comprising host nucleic acids and non-host nucleic acids, wherein the host nucleic acids and the non-host nucleic acids are linked by adapters, and wherein the adapters are linked to the 5' and 3' ends of the host nucleic acids and the non-host nucleic acids; contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to a target site in the host nucleic acid, thereby producing host nucleic acids to which the adapter is linked only on one end and non-host nucleic acids to which the adapter is linked on both the 5' and 3' ends; and amplifying the product with adapter-specific PCR or purifying, or treating with an exonuclease.

[0200] In another embodiment, provided herein is a method for continuously depleting targeted nucleic acids in a sample, comprising: (a) providing a sample comprising host nucleic acids and non-host nucleic acids, wherein the non-host nucleic acids comprise nucleic acids from at least one known non-host organism and nucleic acids from at least one unknown non-host organism; (b) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is configured to hybridize with a targeting sequence in the host nucleic acid, thereby cutting a portion of the host nucleic acid; (c) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is configured to hybridize with a targeting sequence in the at least one known non-host nucleic acid, thereby cutting a portion of the at least one known non-host nucleic acid; and (d) isolating nucleic acid from an unknown non-host organism.

[0201] Figure 1A first non-limiting exemplary method of processing a human tissue sample (1000) is provided. In a first step (1005), DNA extraction extracts substantially all nucleic acid sequences from the sample (1000), including nucleic acid sequences of the human host and nucleic acid sequences of any non-human or non-host organisms present in the sample (1000). The DNA extraction step (1005) can produce about 95% human DNA (1010) and about 5% non-human DNA (1015), wherein the non-human DNA (1015) primarily includes microbial DNA, and in this example method embodiment, the microbial or non-human DNA (1015) is of primary interest for further DNA analysis. After the DNA extraction step (1005), the extracted nucleic acid sequences (1010) and (1015) are fragmented to reduce the length of each extracted nucleic acid sequence to a more manageable length for amplification, sequencing, etc. An adapter (1020) is attached to each end of each fragment. Each extracted nuclear sequence fragment or genomic fragment comprises a region of the genome, for example, each fragment (1025) includes a nucleic acid sequence shown as a dashed line between two joints (1020) from a human genome region, and each fragment (1030) includes a nucleic acid sequence from a region of one of the non-host organisms extracted from a tissue sample as a solid line between two joints (1020). Each extracted nucleic acid or genomic fragment comprises a region of the genome, for example, each fragment (1025) includes a nucleic acid sequence shown as a dashed line between two joints (1020) from a human genome region, and each fragment (1030) includes a nucleic acid sequence from a region of one of the non-host organisms extracted from a tissue sample as a solid line between two joints (1020). However, it will be appreciated that the sequences are indistinguishable without further analysis.

[0202] Exemplary applications of the compositions and methods described herein are Figure 1 Provided in. This figure depicts a non-limiting exemplary embodiment of the present invention, which includes a method for subtracting a DNA extract of a biological sample. Figure 1In the method, the entire fragmented DNA extract (1025) and (1030) and the entire guide RNA library (1050) are mixed with the Cas9 protein in the mixture (1080). In the mixture (1080), each target-specific guide sequence (1060) hybridizes with the matching nucleic acid sequence found in the human DNA fragment (1025), and the Cas9 protein and the guide RNA stem binding site (1065) form a guide RNA / Cas9 complex (1085), which binds the guide RNA (1055) to the human DNA fragment (1025). If the guide RNA library (1050) is well designed, essentially all of the human DNA fragments (1025) will be bound by the guide RNA / Cas9 complex. Thereafter, the mixture (1080) is incubated in a manner such that the Cas9 protein cuts or cleaves both strands of each human DNA fragment (1025) bound to the guide RNA / Cas9 complex. After cleavage, the human DNA fragment (1025) is separated into two pieces (1090) (1095), any uncut DNA fragment (1030) remains intact, and the adapters (1020) remain attached to each end and can be amplified and further studied.

[0203] In various further processing steps performed after the subtractive target has been cleaved or cleaved, the mixture (1080) can be size selectively filtered to separate the uncut fragments (1030) from the cleaved fragments (1090) and (1095). Thereafter, the uncut fragments (1030) can be amplified and sequenced. Alternatively, an amplification process can be used to sort the cleaved segments from the uncut segments, since in some amplification systems, only the segments with adapters (1020) at each end of the fragment are amplified.

[0204] Figure 2 Another exemplary application of the compositions and methods described herein is provided in . Figure 2 A second non-limiting exemplary method is depicted involving processing a sample or sequencing library (2000) that involves segmentation rather than subtraction. In a first step (2005), DNA extraction extracts substantially all nucleic acid sequences from the sample (2000), including nucleic acid sequences of the human host and nucleic acid sequences of any other non-host organisms present in the sample (2000). In this example, the DNA extraction step (2005) can produce about 5 to 40% human DNA and about 95 to 60% non-human DNA. As described above with respect to Figure 1 As described above, the DNA extraction sample is fragmented and the adapter is connected. Figure 1As further described, a guide RNA library (2050) of gRNAs is developed to hybridize with a plurality of different human-specific gRNAs (2055), each of which is configured to hybridize with a human DNA or nucleic acid sequence that is targeted for binding to the Cas9 complex. However, instead of cutting the targeting sequence, Figure 2 The method shown is used to separate the fragmented nucleic acid sample into two fractions that can be amplified separately. As described above, the guide library (2050) and the fragmented DNA extraction sample are combined with the Cas9 in the mixture (2080). However, in the present example embodiment, CAs9 comprises a catalytically inactive Cas9 (dCas9). The term "catalytically inactive" refers to a Cas protein with inactivated HNH and RuvC nucleases. This protein can bind to a target site in double-stranded DNA (wherein the target site is determined by a guide RNA), but the protein cannot cut or nick double-stranded DNA. Therefore, dCas9 separates the mixture (2080) into unbound non-human DNA fragments (2030) and dCas9-bound human DNA fragments (2090). The dCas9 / gRNA complex binds only to the target determined by the gRNA sequence, and the binding portion of the target nucleic acid sample is removed by binding to an affinity tag (e.g., biotin) previously connected to the dCas9 protein. The bound nucleic acid sequence (2090) can be eluted from the Cas9 / gRNA complex by denaturing conditions and then amplified and sequenced. Similarly, the unbound nucleic acid sequence (2030) can be amplified and sequenced.

[0205] Subtraction of large DNA fragments without adapters

[0206] In some embodiments, the methods provided herein are used for subtraction. However, instead of cutting a library containing a joint, a guide RNA is selected to perform multiple cuts in a fragmented DNA library of large size (e.g., anywhere from 100bp to 10kb). After cutting with a CRISPR / Cas system protein-gRNA complex, the DNA is size-selected to remove small fragments (e.g., at least 1 / 2 or 1 / 3 of the average size of a complete fragment). This is assisted, for example, by treatment with a lambda exonuclease, which is a 5' phosphate-specific exonuclease in the 5' to 3' direction, and will attack any fragment previously cut with a CRISPR / Cas system protein. The resulting library can then be sequenced by a single-molecule sequencer that does not require a sequencing joint; or a joint can be connected for downstream analysis.

[0207] Depletion of CRISPR / Cas system proteins using thermostable

[0208] In another embodiment, a method for producing a cut targeting sequence in a sample comprises: (a) providing a sample comprising a sequence of interest and a sequence targeted to be cut; (b) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to the targeting sequence, thereby producing a cut targeting sequence; (c) dissociating the CRISPR / Cas system protein from the cut targeting sequence; (d) producing additional cut targeting sequences; and (c) recovering the uncut target sequence. In some embodiments, the CRISPR / Cas system protein is thermostable. In some embodiments, the dissociation of the CRISPR / Cas system protein from the cut targeting sequence is achieved by increasing the temperature of the mixture of step (b) to at least 75°C. In some embodiments, the generation of additional cut targeting sequences is achieved by reducing the temperature of the mixture of step (b) to at least 50°C.

[0209] In another embodiment, a method for depleting a targeting sequence in a sample comprises: (a) providing a sample comprising a target sequence and a sequence targeted to be depleted; (b) contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to the targeting sequence, thereby producing a cleaved targeting sequence, and wherein the CRISPR / Cas system protein is thermostable; (c) increasing the temperature of the mixture of step (b) to at least 75°C; (d) decreasing the temperature of the mixture of step (b) by at least 50°C; repeating steps (c) and (d) at least once; and (f) recovering the uncleaved target sequence.

[0210] CRISPR / Cas system protein-mediated excision in the presence of CRISPR / Cas protein nickases

[0211] In some embodiments, the elimination of unwanted targeted nucleic acids can be performed using CRISPR / Cas system protein nickases. In one embodiment, the method includes: preparing a DNA sequencing library comprising DNA to be removed (e.g., non-target human DNA) and target DNA (e.g., DNA from an unknown pathogen); designing guide RNA so that all DNA to be eliminated has two adjacent (e.g., less than 15 bases apart) guide RNA binding sites on the opposite DNA strand; adding CRISPR / Cas system protein nickases and guide RNA to the DNA library. In this embodiment, the CRISPR / Cas system protein nickase recognizes the target site on the DNA to be removed and only cuts one strand. For the DNA to be eliminated, two independent CRISPR / Cas system protein nickases can cut the two strands of the DNA to be removed (e.g., human DNA) at adjacent positions; only the DNA to be removed (e.g., human DNA) will have two adjacent CRISPR / Cas system protein nickase sites, which produce double-strand breaks. If the CRISPR / Cas system protein nickase recognizes a site on the target DNA (e.g., pathogenic DNA) non-specifically or with low affinity, it will only cleave one strand which will not prevent subsequent PCR amplification or downstream processing of the DNA molecule. This is shown in Figure 7 In this embodiment, the chance of two guide RNAs non-specifically recognizing two sufficiently adjacent sites is negligible (<1×10-14). This embodiment is particularly useful if conventional CRISPR / Cas system protein-mediated cleavage cuts too much target DNA.

[0212] CRISPR / Cas system protein-mediated depletion and biotin labeling

[0213] In some embodiments, biotin is used to remove CRISPR / Cas system protein cleavage products. For example, in a sample initially containing <5% target DNA and >95% targeted DNA to be eliminated, >95% of the DNA is fragmented and eliminated, while the uncut (<5% target DNA) DNA containing a biotin tag is purified by binding to streptavidin beads. This example illustrates a method for removing unwanted DNA (fragmented DNA eliminated) after CRISPR / Cas system protein-mediated cleavage without the use of exonucleases.

[0214] Fig.10An exemplary embodiment is shown in . In this exemplary embodiment, a DNA mixture (containing >95% of unwanted human DNA and <5% of other target DNA) is fragmented according to a conventional protocol, end-repaired and ligated to a linker, and then amplified by PCR using primers of biotin-P5 (e.g., 5'-biotin-AATGATACGGCGACCACCGA) and P7 (e.g., 5'-CAAGCAGAAGACGGCATACGA). This ensures that the entire sequencing library has a 5' biotin label only at one end of the DNA molecule. The DNA mixture is then digested with a CRISPR / Cas system protein (e.g., Cas9) and complexed with a guide RNA library for, for example, mitochondrial DNA (unwanted DNA) in this case. DNA molecules that have been cut by CRISPR / Cas system proteins (e.g., mitochondrial DNA in this case) lose biotin-labeled links and therefore cannot be sequenced or PCR amplified; while a complete DNA library that has not been cut by Cas9 (e.g., non-mitochondrial target DNA in this case) still carries a biotin label. As a result, intact DNA that has not been cut by CRISPR / Cas system proteins can be recovered by adding streptavidin beads. The samples can then be subjected to further downstream applications such as sequencing, cloning, and further enrichment.

[0215] Exonuclease treatment after subtraction

[0216] In some embodiments, it is desirable to remove the cleaved fragments prior to PCR amplification or sequencing.

[0217] In one embodiment, CRISPR / Cas system protein-mediated depletion is followed by exonuclease treatment. Exonuclease treatment can further degrade nucleic acids cleaved by CRISPR / Cas system proteins while leaving uncut nucleic acids containing the target sequence intact.

[0218] In one embodiment, the method of eliminating the targeting sequence in the sample comprises: providing a sample comprising a target sequence and a sequence targeted to be eliminated; contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to the targeting sequence, thereby generating a cleaved targeting sequence; and contacting the product of step (b) with a nuclease. In one embodiment, the nuclease is exonuclease III. In another embodiment, the exonuclease is BAL-31.

[0219] In an exemplary embodiment, DNA is extracted from a biological sample and fragmented to produce a library (e.g., a sequencing library) comprising DNA fragments. A Y-shaped adapter or a circular adapter is connected to the DNA fragment. The DNA fragment comprises a DNA target sequence and a targeting sequence (non-target DNA). The library is contacted with a plurality of CRISPR / Cas system protein-gRNA complexes, and the CRISPR / Cas system protein cuts the non-target target DNA and retains other DNA target sequences intact. The resulting product is contacted with exonuclease III. Exonuclease III can cause unidirectional 3'>5' degradation of a DNA chain by using a flat end or a 5' overhang, producing single-stranded DNA and nucleotides; it is not active on single-stranded DNA, so the 3' overhang (e.g., Y-shaped adapter end) is resistant to degradation. Therefore, the complete double-stranded DNA library that is not cut by the CRISPR / Cas system protein is not digested by exonuclease III, and the DNA molecules cut by the CRISPR / Cas system protein are degraded by the flat end cut out of Cas9 by exonuclease III with 3'>5' activity. Figure 8 An exemplary embodiment is shown. According to conventional protocols, the DNA mixture (containing >95% unwanted human DNA and <5% other target DNA) is fragmented, end-repaired and ligated to a Y-shaped adapter (or circular adapter), but not amplified by PCR. The DNA mixture is then digested with Cas9, complexed with a guide RNA library for mitochondrial DNA, for example, in this case, and nuclease III is added. The unwanted mitochondrial DNA is digested, and the remaining intact double-stranded DNA library is then recovered by column purification and / or PCR amplification.

[0220] In another exemplary embodiment, exonuclease BAL-31 is used to degrade DNA cut by CRISPR / Cas system proteins while retaining uncut target DNA intact. In an exemplary embodiment, DNA is extracted and fragmented from a biological sample, and a library (e.g., a sequencing library) comprising DNA fragments is generated. The DNA fragments comprise a DNA target sequence and a targeting sequence (non-target DNA). The 3' end of the fragment is added with a poly-dG tail using a terminal transferase. The library is contacted with multiple CRISPR / Cas system protein-gRNA complexes, and the CRISPR / Cas system protein cuts non-target target DNA, and retains other DNA target sequences intact. The resulting product is contacted with exonuclease BAL-31. Exonuclease BAL-31 has two activities: double-stranded DNA exonuclease activity and single-stranded DNA / RNA endonuclease activity. Double-stranded DNA exonuclease activity allows BAL-31 to degrade DNA from the open end on both chains, thereby reducing the size of double-stranded DNA. The longer the incubation time, the more the size of the double-stranded DNA is reduced, making it useful for the reduction of medium to large DNA (>200bp). Note that the single-stranded endonuclease activity of BAL-31 enables it to digest poly-A, poly-C or poly-T very quickly, but the digestion of poly-G is extremely low (Marrone and Ballantyne, 2008). Due to this property, adding a single-stranded poly-dG at the 3' end of the library can protect it from being degraded by BAL-31. Therefore, DNA molecules cut by CRISPR / Cas system proteins can be degraded by BAL-31, and the degradation is carried out by the double-stranded DNA exonuclease activity of BAL-31 from the double-stranded flat end cut by the CRISPR / Cas system protein to the other end carrying poly-dG, causing reduction; and the complete DNA library that is not cut by the CRISPR / Cas system protein is not digested by BAL-31, which is due to its 3' end poly-dG protection. Fig. 9 An exemplary embodiment of the method is depicted. A sequencing library (containing, for example, >95% human DNA and <5% other libraries) is prepared. A poly-dG tail is added to the 3' end using terminal transferase. The library with the poly-dG tail is then digested with Cas9 and complexed with a guide RNA library (e.g., a guide RNA library for mitochondrial DNA). The product is then incubated with the exonuclease BAL-31, which initiates digestion of the ends that are not capped with poly-dG. The product is then subjected to further PCR or purified on a DNA purification column. The remaining intact double-stranded DNA library can then be recovered by column purification or PCR amplification.

[0221] Controls for monitoring abatement

[0222] In the embodiments discussed, it is desirable to provide positive and / or negative controls. Positive controls can ensure that the depletion of the target nucleic acid is performed with fidelity.

[0223] In some embodiments, a control reagent set is a positive control reagent set, a positive control target sequence. In an exemplary embodiment, the positive control reagent set comprises a collection of nucleic acid fragments, wherein the fragments comprise a target sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% complementary to the gRNA. This control can be run with the user's reaction to ensure that all components are working properly. After protein reduction using the CRISPR / Cas system, the removal of the positive control target sequence can be measured by gel electrophoresis or qPCR.

[0224] In some embodiments, the control reagent group is a negative control reagent group. In some embodiments, Negative control ensures that off-target cutting is minimal or absent. In an exemplary embodiment, the negative control reagent group includes a second group of gRNA, wherein compared with the first group of gRNA, The second group of gRNA shows reduced binding to the target sequence. In some embodiments, compared with the first group of RNA, the second group of gRNA shows a reduction of 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80% or 85% binding to the target sequence. In another exemplary embodiment, the negative control reagent group includes a second group of gRNA, wherein the second group of gRNA is no more than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% complementary to the target sequence. A negative control can be a set of gRNAs that have less than 100% identity with the gRNA used; for example, 1, 2, 3, 4, 5 or more mismatches with the target-specific sequence. In some embodiments, the negative control reagent set comprises a collection of nucleic acid fragments, wherein the fragments are no more than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% complementary to the first set of gRNAs. The DNA library can have less than 100% identity with the targeting sequence of the gRNA used in the kit; for example, 1, 2, 3, 4, 5 or more mismatches with the complementary sequence of the gRNA. This control can be run with the user's reaction to ensure that all components are working properly and to measure any off-target activity of the enzyme. After subtraction with CRISPR / Cas system proteins, the amount of off-target subtraction can be measured by gel electrophoresis or qPCR.

[0225] With regard to the positive and negative controls considered herein, the complementarity of the gRNA provided herein to its target can refer to the complementarity of the gRNA along the full length of the target. However, in some embodiments, in the binding region closest to the PAM sequence, complementarity may be more affected by the mismatch of the nucleic acid at the end of the gRNA. Mismatches in this region may affect the ability to bind to the target more than mismatches of nucleic acids along other regions of the gRNA. Similarly, mismatches in the gRNA away from the PAM sequence may affect the ability to bind to the target less than mismatches of nucleic acids along other regions of the gRNA. In some embodiments, the negative control gRNA has lower complementarity near the PAM sequence, but has higher complementarity away from the PAM sequence. For example, in some embodiments, the negative control gRNA has 50%-70% complementarity near the PAM sequence, but has 70%-100% complementarity away from the PAM sequence. In some embodiments, the negative control gRNA has 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% complementarity along the entire length of the target.

[0226] Subtraction of mitochondrial DNA after ATAC-seq

[0227] The transposase accessible chromatin sequencing assay technology using sequencing (ATAC-seq) is used in molecular biology to study chromatin, i.e., accessible sites. The method uses sequencing adapters to tag open chromatin regions by transposase, so that DNA fragments from these open chromatin regions can be amplified and high-throughput sequencing can be performed (WO2014 / 189957; Buenrostro et al., Nature Methods, Vol.10, No.12, December 2013, p. 1213). Although ATAC-seq requires much less starting material than other assays for whole-genome chromatin accessibility, one of the main drawbacks is that sequencing libraries are usually contaminated by a high percentage of mitochondrial DNA (which is also open DNA), and more sequencing reads are required for standard accessibility studies of many human genomes, such as DNase-seq and FAIRE-seq (M.Temana and MJ.Back, 2014). Therefore, there is a need in the art to remove unwanted mitochondrial DNA contaminants from sequencing libraries after the ATAC-Seq method to reduce sequencing costs. The present invention provides methods for selectively depleting mitochondrial DNA from samples subjected to ATAC-Seq.

[0228] Provided herein is a method for analyzing genomic DNA, comprising: (a) treating DNA isolated from a cell population with an insertion enzyme to produce a plurality of non-mitochondrial genomic DNA fragments with tags, thereby also producing a residual amount of mitochondrial DNA with tags; (b) enriching the non-mitochondrial DNA in the product of step (a) according to any relevant method provided herein. In some embodiments, the method further comprises sequencing at least a portion of the tagged fragments to produce a plurality of sequence reads; and making an epigenetic map of a region of the cell genome by mapping information obtained from the sequence reads to the region.

[0229] In another aspect, the present disclosure provides a method for helping to determine the accessibility of a polynucleotide at a site, wherein the polynucleotide is from a cell sample, the method comprising: inserting a plurality of molecular tags into the polynucleotide with an insertion enzyme, and determining the accessibility at the site with the molecular tags, and removing unwanted DNA contaminants using the CRISPR / Cas system-based elimination method described herein. The cell sample can be from a primary source. The cell sample can be composed of a single cell. The cell sample may be composed of a limited number of cells (e.g., less than about 500,000 cells).

[0230] An insertion enzyme can be any enzyme capable of inserting a nucleic acid sequence into a polynucleotide. In some cases, an insertion enzyme can insert a nucleic acid sequence into a polynucleotide in a substantially sequence-independent manner. An insertion enzyme can be prokaryotic or eukaryotic. Examples of insertion enzymes include, but are not limited to, transposases, HERMES, and HIV integrase. The transposase can be a Tn transposase (e.g., Tn3, Tn5, Tn7, Tn10, Tn552, Tn903), a MuA transposase, a Vibhar transposase (e.g., from Vibrio harveyi), Ac-Ds, Ascot-I, BsI, Cin4, Copia, En / Spm, an F element, hobo, Hsmarl, Hsmar2, IN (HIV), ISI, IS2, IS3, IS4, IS5, IS6, ISIO, IS2I, IS30, IS50, ISSI, ISI50, IS256, IS407, IS427, IS630, IS903, IS911, IS982, IS103I, ISL2, LI, Mariner, P element, Tam3, Tel, Tc3, Tel, THE-I, Tn / O, TnA, Tn3, Tn5, Tn7, TnlO, Tn552, Tn903, Toll, Tol2, TnlO, Tyl, any prokaryotic transposase, or any transposase related to and / or derived from those described above. In some cases, a transposase related to and / or derived from a parent transposase can comprise a peptide fragment having at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% amino acid sequence homology to the corresponding peptide fragment of the parent transposase. The length of the peptide fragment can be at least about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 60, about 70, about 80, about 90, about 100, about 150, about 200, about 250, about 300, about 400 or about 500 amino acids. For example, a transposase derived from Tn5 can comprise a peptide fragment that is 50 amino acids in length and is about 80% homologous to the corresponding fragment in the parent Tn5 transposase. In some cases, insertion can be promoted and / or triggered by the addition of one or more cations. The cation can be a divalent cation, such as Ca. 2+ ,Mg 2+ and Mn 2+ .

[0231] Molecular tags can include sequencing adapters, locked nucleic acids (LNA), zipper nucleic acids (ZNA), RNA, affinity reactive molecules (e.g., biotin, dig), self-complementary molecules, phosphorothioate modifications, azido or alkynyl. In some cases, sequencing adapters can also include barcode markers. In addition, the barcode marker can include a unique sequence. The unique sequence can be used to identify each insertion event. Any label can also include a fluorescent label (e.g., fluorescein, rhodamine, Cy3, Cy5, thiazole orange, etc.).

[0232] Kits and Products

[0233] The present application provides a kit comprising any one or more compositions described herein (which are not limited to linkers, gRNAs, gRNA libraries, etc.).

[0234] In one embodiment, the kit comprises a collection or library of gRNAs, wherein the gRNAs target human DNA sequences. In another embodiment, the kit comprises a collection or library of gRNAs, wherein the gRNAs target bovine DNA sequences. In another embodiment, the kit comprises a collection or library of gRNAs, wherein the gRNAs target human ribosomal RNA sequences. In another embodiment, the kit comprises a collection or library of gRNAs, wherein the gRNAs target human mitochondrial DNA sequences.

[0235] In some embodiments, the kit comprises: a CRISPR / Cas system protein and a gRNA, wherein the gRNA is complementary to mitochondrial DNA; or wherein the gRNA is complementary to the entire genome; or wherein the gRNA is complementary to a cDNA prepared from the entire transcriptome; or wherein the gRNA is complementary to at least 10, at least 25, at least 50, at least 100, at least 250, at least 500, at least 750, at least 10 2 , at least 10 3 At least 10 4 At least 10 5 At least 10 6 At least 10 7 At least 10 8 At least 10 9 At least 10 10or wherein the gRNA is complementary to a cDNA made from the most abundant transcript in the transcriptome, such as the 100, 75, 50, 25, 20, 15, or 10 most abundant transcripts in the transcriptome; or wherein the gRNA is complementary to a cDNA made from a subset of the 100, 75, 50, 25, 20, 15, or 10 most abundant transcripts in the transcriptome.

[0236] In some embodiments, the kit comprises: a CRISPR / Cas system protein and a gRNA, wherein the CRISPR / Cas system protein comprises a mixture of CRISPR / Cas system proteins from different bacteria; or wherein the CRISPR / Cas system protein is engineered; wherein the gRNA is complementary to mitochondrial DNA; or wherein the gRNA is complementary to genomic DNA, representing the entire genome; or wherein the gRNA is complementary to a cDNA library derived from the entire transcriptome; or wherein the gRNA is complementary to a cDNA library derived from at least 10, at least 25, at least 50, at least 100, at least 250, at least 500, at least 750, at least 10 2 At least 10 3 At least 10 4 At least 10 5 At least 10 6 At least 10 7 At least 10 8 At least 10 9 At least 10 10 or wherein the gRNA is complementary to a cDNA library derived from the 100, 75, 50, 25, 20, 15, or 10 most abundant transcripts in the transcriptome; or wherein the gRNA is complementary to a cDNA library derived from a subset of the 100, 75, 50, 25, 20, 15, or 10 most abundant transcripts in the transcriptome; or wherein the gRNA comprises a mixture of gRNAs capable of targeting CRISPR / Cas system proteins from different bacterial species to a target sequence.

[0237] In some embodiments, the kit comprises: a CRISPR / Cas system protein, a gRNA, and an enzyme having exonuclease activity, wherein the gRNA is complementary to the target of interest. In one embodiment, the exonuclease is exonuclease III. In one embodiment, the exonuclease is BAL-31.

[0238] In some embodiments, the kit comprises: a CRISPR / Cas system protein and a gRNA, wherein the CRISPR / Cas system protein is thermostable; wherein the gRNA is complementary to a target of interest.

[0239] In some embodiments, the kit comprises: CRISPR / Cas system proteins, a first group of gRNAs and a control reagent group, wherein the gRNA is complementary to the target sequence of interest. In one embodiment, the control reagent group is a positive control reagent group. In an exemplary embodiment, the positive control reagent group comprises a collection of nucleic acid fragments, a positive control target sequence, wherein the fragment comprises a target sequence complementary to the gRNA. In one embodiment, the control reagent group is a negative control reagent group. In an exemplary embodiment, the negative control reagent group comprises a second group of gRNAs, wherein the second group of gRNAs exhibits reduced binding to the target sequence compared to the first group of gRNAs. In another exemplary embodiment, the negative control reagent group comprises a collection of nucleic acid fragments, wherein the fragments are no more than 90% complementary to the first group of gRNAs.

[0240] In some embodiments, the kit comprises: a reagent for isolating DNA from a cell population; an insertion enzyme; a CRISPR / Cas system protein; and a plurality of gRNAs, wherein the gRNA is complementary to mitochondrial DNA; or wherein the gRNA is complementary to the entire genome; or wherein the gRNA is complementary to the entire transcriptome; or wherein the gRNA is complementary to the top 100, 75, 50, 25, 20, 15, or 10 genes in the transcriptome.

[0241] The present application also provides an article of manufacture comprising any one of the kits described herein.Examples of articles of manufacture include vials (including sealed vials).

[0242] The following examples are included for illustrative purposes and are not intended to limit the scope of the present invention. Example

[0243] Example 1: Subtraction of mitochondrial DNA from ATAC-seq libraries, Library 1

[0244] Overview

[0245] like Figure 4 As shown, the subtraction method was tested on a human DNA library that had been previously sequenced and shown to consist of 94% human nuclear DNA and 6% mitochondrial DNA (library 1). Subtraction was performed using recombinant Cas9 and a library of 25 guide RNAs designed specifically for mitochondrial DNA. A control subtraction was performed using an unrelated guide RNA that does not target mitochondrial DNA. Approximately 40% of human mitochondrial DNA was subtracted. Subtraction was completed within 20 minutes, followed by PCR amplification of the library.

[0246] Expression of Cas9

[0247] Cas9 (from Streptococcus pyogenes) was cloned into the pET30 expression vector (EMD biosciences) to insert a six-histidine tag immediately upstream of the Cas9 start codon. The resulting plasmid was transformed into the Rosetta (DE3) BL21 bacterial strain (EMD biosciences) and cultured in 1L of LB medium with sufficient ventilation until the optical density (OD at 600nm) of the culture reached 0.4. The temperature was lowered to 25°C, 0.2mM IPTG was added, and cultured for another 4 hours. The cells were then collected by centrifugation (1,000× g at 4°C for 20 minutes), resuspended in 10ml binding buffer (20mM Tris pH8, 0.5M NaCl, 5mM imidazole, 0.05% NP40), and lysed by ultrasonic treatment (7×10 second bursts at 30% power, Sonifier 250, Branson). Insoluble cell debris was removed by centrifugation at 10,000 x g for 20 minutes; the supernatant containing soluble proteins was then mixed with 0.4 ml NTA beads (Qiagen) and loaded onto the column. The beads were washed three times with 4 ml binding buffer and then eluted with 3 × 0.5 ml binding buffer supplemented with 250 mM imidazole. The eluted fractions were then concentrated using a 30,000 MWCO protein concentrator (Life Technologies) and buffer exchanged with storage buffer (10 mM Tris pH 8, 0.3 M NaCl, 0.1 mM EDTA, 1 mM DTT, 50% glycerol), verified by SDS PAGE followed by colloidal blue staining (Life Technologies), quantified, and then stored at -20 ° C for later use.

[0248] The mutant Cas9 nickase, a D10A mutant of Streptococcus pyogenes Cas9, was prepared and purified using the same method as described above for producing Cas9.

[0249] Preparation of guide RNA library

[0250] 25 constructs were designed, each containing a T7 RNA polymerase promoter, a 20 base pair mitochondrial DNA specific sequence, and a guide RNA backbone from Streptococcus pyogenes. For each construct, two oligonucleotides (see Tables 1 and 2 for sequences) were arranged and combined at a final concentration of 5 μM in 1 μl, then heated at 98°C for 3 minutes, then cooled to 55°C at a rate of 5°C / min, and finally incubated at 55°C for 5 minutes.

[0251] The annealed oligonucleotides were then ligated to a T7GRNE vector containing a guide RNA backbone by golden gate cloning; the annealed oligonucleotides were combined to 500 ng of T7GRNE plasmid, 1 μl of BsaI restriction enzyme and 1 μl of T7 DNA ligase in a total volume of 20 μl. The reactions were subjected to 10 cycles in a thermal cycler as follows: incubation at 37°C for 15 minutes, then at 20°C for 10 minutes, followed by a single cycle at 80°C for 15 minutes. The products were then PCR amplified using a specific forward primer (see Tables 1 and 2) and a reverse primer (5'-CAGAGCGAGGTATGTAGG-3'). The cycling conditions were as follows: 95°C for 1 minute, 57°C for 30 seconds, and 72°C for 90 seconds for 30 cycles. A successful reaction was confirmed by the presence of a 1.6 kb fragment by agarose gel electrophoresis and SYBR safe staining. Successful reactions were pooled together and purified using a PCR cleanup kit (Thermo Fisher Scientific).

[0252] Use the following rules to design guide RNA:

[0253] Rule 1: Create the following sequence in the target genomic region (e.g., whole exon or mitochondrial genome) on any strand (5'>3' direction): NNNNNNNNNNNNNNNNNNNN NGG

[0254] Rule 2: The underlined sequence (20-mer) is the targeting portion of the guide RNA contained in the aligned oligonucleotide sequence.

[0255] a. Any 20-mer with more than 55% GC content is eliminated

[0256] b. Any 20-mers with more than 13 stem-loop forming base pairs (e.g. predicted by Mfold or Vienna software) were eliminated

[0257] c. If the first nucleotide of the 20-mer is not A / G, add a G residue to the 5' end to make a 21-mer

[0258] d. Rule 3: Add T7 promoter and primer binding site to generate the following primers (5'>3'):

[0259] GCCTCGAGCTAATACGACTCACTATAG(G) NNNNNNNNNNNNNNNNNNNN

[0260] (G) indicates that if the 20-mer has no purine at the 5' end, G is added

[0261] In vitro transcription

[0262] To transcribe the guide library into guide RNA, we assembled the following in vitro transcription reaction mixture: 10 μl of purified library (~500 ng), 6.5 μl of H2O, 2.25 μl of ATP, 2.25 μl of CTP, 2.25 μl of GTP, 2.25 μl of UTP, 2.25 μl of 10x reaction buffer (NEB), and 2.25 μl of T7 RNA polymerase mix. The reaction was incubated at 37°C for 24 hours and then diluted 10-fold in H2O. A single reaction produced approximately 40 μg of RNA. The yield and size of the RNA (~150 base pairs) were checked by running 1 μl of the reaction on a 5% TBE / urea gel and staining with SYBR Gold (Life Technologies).

[0263] DNA-specific Cas9-mediated excision

[0264] The diluted guide RNA (1 μl, equivalent to 2 pmol) was combined with 3 μl 10x Cas9 reaction buffer (NEB), 20 μl H2O and 1 μl recombinant Cas9 enzyme (NEB, 1 pmol / μl). Control reactions using control guide RNA targeting the following sequence (5'-GGATTTATACAGCACTTTAA-3') were performed separately using the same parameters. This sequence is not present in human chromosomes or mitochondrial DNA. The reaction was incubated at 37°C for 15 minutes, then supplemented with 5 μl of diluted DNA library (50 pg / μl) and continued to be incubated at 37°C for 90 minutes. The reaction was terminated by adding RNase A (Thermo Fisher Scientific) at a dilution of 1:100, heated to 98°C for 5 minutes, then cooled to room temperature and added 100 μl H2O. The reaction was then stored at -20°C until use.

[0265] Quantification of mitochondrial DNA after subtraction

[0266] For each reaction (each test condition and reaction using control guide RNA), two separate 5 μl samples were analyzed by real-time PCR using control and test primers. For control primer reactions, samples were incubated with 2 μl H2O, 0.25 μl 10 μM primer P5 (5'-AATGATACGGCGACCACCGA-3') and 0.25 μl 10 μM P7, (5'-CAAGCAGAAGACGGCATACGA-3') and 7.5 μl of 2x Maxima SYBR Green master mix (Thermo Fisher Scientific). For test primer reactions, samples were incubated with 1.75 μl H2O, 0.5 μl of 10 μM mitochondrial primers (see Tables 1 and 2) and 0.25 μl of 10 μM P7 (5'-CAAGCAGAAGACGGCATACGA-3') and 7.5 μl of 2x Maxima SYBR Green master mix (Thermo Fisher Scientific). Reactions were incubated in an iCycler real-time PCR thermocycler (BioRad) using the following 2-step cycling conditions: 95°C for 3 min, followed by 40 cycles of 95°C for 10 sec, 55°C for 45 sec.

[0267] A calibration curve was performed for both real-time PCR conditions using control and test primers. The diluted DNA library (50 pg / μl) was further diluted 1:10, 1:100, 1:1000, 1:10,000 and these dilutions were analyzed by real-time PCR using the same reaction conditions, instrument and cycling conditions as above.

[0268] The amount of total DNA and mitochondrial DNA was derived from the results of the control and test primer reactions, respectively. For each DNA library subtraction experiment, the mitochondrial DNA:total DNA ratio was determined and normalized to the experiment using a control guide RNA and then plotted as Figure 4 The bar graph shown.

[0269] Table 1: Forward primers – used in annealing and subsequent PCR reactions

[0270]

[0271]

[0272] Table 2: Reverse primers – used in annealing reaction and real-time PCR reaction

[0273]

[0274]

[0275] Example 2: Subtraction of mitochondrial DNA from ATAC-seq libraries, library 2

[0276] Overview

[0277] like Figure 5 As shown in Figure 6, the subtraction method was tested in a human DNA library that had been previously sequenced and shown to consist of 55% human nuclear DNA and 45% mitochondrial DNA (library 2). Subtraction was performed using recombinant Cas9 and a library of 90 guide RNAs specifically designed for mitochondrial DNA, leaving no gaps in the mitochondrial genome. A control subtraction was performed using an unrelated guide RNA that does not target mitochondrial DNA.

[0278] Pre- and post-capture libraries were quantified by real-time PCR using two different sets of primer combinations: P5 and P7, which amplify all DNA library fragments or mitochondrial DNA-specific primers that amplify only mitochondrial DNA. The ratio of these two separate reactions was used to quantify the depletion of mitochondrial DNA.

[0279] Pre- and post-capture libraries were also sequenced on the Illumina MiSeq platform and the resulting reads were mapped to the human genome to determine mitochondrial DNA content.

[0280] Expression of Cas9

[0281] Cas9 (from Streptococcus pyogenes) was cloned into the pET30 expression vector (EMD biosciences) to insert a six-histidine tag immediately upstream of the Cas9 start codon. The resulting plasmid was transformed into the Rosetta (DE3) BL21 bacterial strain (EMD biosciences) and cultured in 1L LB medium with sufficient ventilation until the optical density (OD at 600nm) of the culture reached 0.4. The temperature was lowered to 25°C, 0.2mM IPTG was added, and cultured for another 4 hours. The cells were then collected by centrifugation (1,000×g at 4°C for 20 minutes), resuspended in 10ml binding buffer (20mM Tris pH8, 0.5MNaCl, 5mM imidazole, 0.05% NP40), and lysed by ultrasound (7×10 second pulses at 30% power, Sonifier250, Branson). Insoluble cell debris was removed by centrifugation at 10,000 x g for 20 minutes; the supernatant containing soluble proteins was then mixed with 0.4 ml NTA beads (Qiagen) and loaded onto the column. The beads were washed three times with 4 ml binding buffer and then eluted with 3 × 0.5 ml of binding buffer supplemented with 250 mM imidazole. The eluted fractions were then concentrated using a 30,000 MWCO protein concentrator (Life Technologies) and buffer exchanged with storage buffer (10 mM Tris pH 8, 0.3 M NaCl, 0.1 mM EDTA, 1 mM DTT, 50% glycerol), verified by SDS PAGE, subsequently stained with colloidal blue (Life Technologies), quantified, and then stored at -20 ° C for later use.

[0282] The mutant Cas9 nickase, a D10A mutant of Streptococcus pyogenes Cas9, was prepared and purified using the same method as described above for producing Cas9.

[0283] Preparation of guide RNA library

[0284] T7 guide RNA oligonucleotides (Table 3) and the isolated oligonucleotide, stlgR (sequence, GT TTT AGA GCTAGA AAT AGC AAG TTA AAA TAA GGC TAG TCC GTT ATC AAC TTG AAA AAG TGG CAC CGAGTC GGT GCT TTT TTT GGA TCC GAT GC) were sequenced and synthesized (IDT).

[0285] According to the manufacturer's instructions, stlgR oligonucleotides (300 pmol) were sequentially 5'phosphorylated using T4 PNK (New England Biolabs) and then 5' adenylated using a (sing) 5' adenylation kit (New England Biolabs). T7-guide RNA oligonucleotides (5 pmol) and 5' adenylated stlgR (10 pmol) were then ligated at 65°C for 1 hour using a thermostable 5'App DNA / RNA ligase (New England Biolabs). The ligation reaction was heat-inactivated at 90°C for 5 minutes and then PCR (using OneTaq, New England Biolabs, 30 cycles as follows: 95°C for 30 seconds, 57°C for 20 seconds, 72°C for 20 seconds) with primers ForT7 (sequence GCC TCG AGC TAA TAC GAC TCA C) and gRU (sequence AAAAAAAGCACCGACTCGGTG). PCR products were purified using a PCR cleanup kit (Life Technologies) and verified by agarose gel electrophoresis and sequencing.

[0286] The validated product was then used as a template for an in vitro transcription reaction using the HiScribe T7 transcription kit (New England Biolabs). 500-1000 ng of template was incubated overnight at 37°C according to the manufacturer's instructions. The resulting guide RNA was purified using an RNA cleanup kit (Life Technologies), eluted into 100 μl of RNase-free water, quantified and stored at -20°C until use.

[0287] In vitro transcription

[0288] To transcribe the guide library into guide RNA, we assembled the following in vitro transcription reaction mixture: 10 μl of purified library (~500 ng), 6.5 μl of H2O, 2.25 μl of ATP, 2.25 μl of CTP, 2.25 μl of GTP, 2.25 μl of UTP, 2.25 μl of 10x reaction buffer (NEB), and 2.25 μl of T7 RNA polymerase mix. The reaction was incubated at 37°C for 24 hours and then diluted 10-fold in H2O. A single reaction produced approximately 40 μg of RNA. The yield and size of the RNA (~150 base pairs) were checked by running 1 μl of the reaction on a 5% TBE / urea gel and staining with SYBR Gold (Life Technologies).

[0289] DNA-specific Cas9-mediated excision

[0290] Select multiple guide RNAs (from single or multiple in vitro transcription reactions) to ensure that >95% of the target DNA to be subtracted contains at least one guide RNA target sequence. This can be calculated by measuring the distribution of library sizes and determining the mean N and standard deviation SD; for >95% of libraries, N-2SD=minimum size, ensuring that each size has a guide RNA to ensure >95% subtraction. This can also be described as the maximum distance between guide RNAs=average value of library size-2×(standard deviation of library size). In the case of mitochondrial libraries, the library contains DNA fragments with an average length of 450 base pairs and a standard deviation of 100. This results in a maximum of 250bp between guide RNAs. Here, the average length of DNA fragments in these libraries is 450bp (estimated standard deviation is 100bp), assuming a normal distribution, <5% of DNA is less than 250bp. Assuming that the guide RNA will target 100% of its designated target, >95% of the target DNA should contain at least one guide RNA site and be subtracted.

[0291] In this example, all guides constructed in Example 2 were used in addition to those constructed in Example 1. These multiple guide RNAs were mixed in equimolar amounts to increase to a total of 80 pmol, and then mixed with 40 pmol of purified Cas9 protein in 60 μl Cas9 reaction buffer (20 mM HEPES pH 6.5, 100 mM NaCl, 5 mM MgCl2, 0.1 mM EDTA) and incubated at 37 ° C for 10 minutes. 5 ng of DNA mixture (containing the desired DNA and the target DNA to be subtracted) was added and incubated for another 20 minutes. The reaction was terminated by adding 140 μl of TE buffer (10 mM Tris pH 8, 1 mM EDTA) containing 2 μg / ml RNase A and incubated at 37 ° C for 20 minutes. DNA was recovered using a PCR cleanup kit (Life Technologies), and no isopropanol was added before column binding and eluted in 20 μl of 10 mM Tris pH 8. Eluted DNA was re-amplified with HiFidelity Master Mix (New England Biolabs) according to the manufacturer's instructions using appropriate primers (eg, P5 and P7 for re-amplification of Illumina-based DNA sequencing libraries) and 8-13 PCR cycles.

[0292] Sequencing and bioinformatics

[0293] Purify the PCR product using a PCR clean-up kit and use it as a template for high-throughput DNA sequencing (Illumina MiSeq or NextSeq).

[0294] Fastq files were aligned to the human genome reference (hg20) using bwa or bowtie to determine the proportion of reads mapping to the nuclear genome versus the mitochondrial genome.

[0295] Table 3 - Other guide RNAs used in Example 2

[0296]

[0297]

[0298]

[0299] Example 3: Using the CRISPR / Cas9 system to eliminate all human DNA from a DNA library (transcriptome or whole genomic DNA) sequence

[0300] Transcriptome-wide gRNA library:

[0301] Guide RNAs are generated and distributed throughout the transcriptome. The design is based on the blood transcriptome. Based on the knowledge that there is an NGG site every 10-20bp on average in the human genome, a computational selection channel for guide RNAs that span every 100-200bp interval of each transcript was developed. In this way, Considering the typical RNA-seq library insert size of 200-500bp, each insert is expected to contain a target site. After the design is completed, oligonucleotide libraries containing guide RNA target sequences and surrounding motifs are arranged, This allows the invariant part of the T7 promoter and guide RNA sequence to be added subsequently. This method can regenerate the library for a period of time before a new library needs to be arranged. Based on an array size of 90,000 elements, it is expected that each guide RNA will be spaced every 200bp in a transcriptome span with two arrays (assuming a transcriptome size of 30M bases). As described in the previous embodiment, these guide RNAs are then used together with Cas9 to eliminate all human DNA from the RNA-seq library. Subtraction and sequencing data analysis are completed according to the previous embodiment.

[0302] verify:

[0303] The method was tested in test RNA-seq libraries. These RNA-seq libraries were made from a mixture of human and E. coli RNA to simulate the type of sequence being targeted. Sequencing was performed after subtracting the library to obtain ~10X transcriptome coverage. The proportion of all sequences mapped to human before and after subtraction was measured as described above; the statistical significance of the subtraction can be determined using the Kruskal-Wallis one-way ANOVA test.

[0304] This approach is expected to have an optimal gRNA design that modulates Cas9 levels in the reaction to achieve 90% depletion of non-ribosomal human sequences from an RNA-seq library, while depletion of non-human sequences is less than 5%.

[0305] Example 4: Enrichment of Virus or Other Pathogen-derived Sequences from Human Blood Samples

[0306] A human blood sample carrying a known pathogen (e.g., Ebola virus) or an unknown pathogen is obtained, and RNA is extracted (e.g., using a PAXgene Blood RNA extraction kit, Qiagen), and converted into a sequencing library (e.g., using a KAPA RNA-seq library preparation kit) using standard methods. After cDNA generation and adapter ligation, the library is then mixed with a Cas9 and guide RNA library that targets every ~200 bases in the human transcriptome. The reaction is incubated at 37°C for 20 minutes so that any fragment containing the target sequence is cut by Cas9. The library is then purified and amplified using adapter-specific primers. Human sequences are effectively subtracted. Only uncut sequences are amplified, and the resulting library is enriched for viral or pathogen-derived sequences.

[0307] Example 5: Enrichment of samples from livestock for viruses and other pathogens for monitoring

[0308] In this example, the method is used to monitor viruses and other pathogens in milk and livestock.

[0309] RNA from milk or bovine (cow) blood is extracted and converted into a sequencing library as described in the above examples. After cDNA generation and adapter ligation, the library is mixed with Cas9 and a guide RNA pool targeting ~200 bases in the transcriptome of domestic cattle (Bos taurus). The reaction is incubated at 37°C for 20 minutes to allow any fragments containing the target sequence to be cut by Cas9. The library is then purified and amplified using adapter-specific primers. The bovine sequence is effectively subtracted. Only the uncut sequence is amplified, and the resulting library is enriched for viral or pathogen-derived sequences. In this case, the cow-subtracted sequencing library can be sequenced and used to monitor viruses and other pathogens in milk and livestock.

[0310] Example 6: Subtraction of large DNA fragments without adapters

[0311] This embodiment shows a method for supporting subtraction without the need for a joint. In this embodiment, the method is used for the subtraction experiment described in the above embodiment. However, the library containing the joint is no longer cut, but the guide RNA is selected to cut multiple times in a fragmented DNA library of large size (e.g., anywhere from 100bp to 10kb). After cutting with the Cas9 / gRNA complex, the DNA is size-selected to remove small fragments (e.g., at least 1 / 2 or 1 / 3 of the average size of the complete fragment). This can be assisted, for example, by treatment with lambda exonuclease (which is a 5' phosphate-specific exonuclease running in the 5' to 3' direction, and will attack any fragment previously cut with Cas9). The resulting library can then be sent to a sequencing single-molecule sequencer that does not require a sequencing joint for processing; or the joint can be connected for downstream analysis.

[0312] Example 7: Subtraction followed by exonuclease III treatment

[0313] In some embodiments, it is desirable to remove the cleaved fragments prior to PCR amplification or sequencing.This example illustrates a method for removing unwanted DNA after Cas9-mediated cleavage by using exonuclease III to degrade the cleaved DNA while retaining the uncut DNA of interest.

[0314] like Figure 8 As shown, following conventional protocols, a DNA mixture (containing ≥95% human DNA targeted for subtraction and <5% other DNA of interest) is fragmented, end-repaired, and ligated to a Y-shaped adapter (or a The DNA mixture was then digested with Cas9 and complexed with (in this case) a guide RNA library targeting mitochondrial DNA as described previously. The Cas9 reaction was diluted 1:3 with TE (10 mM Tris-Cl pH8, 1 mM EDTA) supplemented with 0.5% RNase A (Thermo Fisher Scientific) and incubated at 37°C for 5 minutes. Proteinase K (NEB) was then added at a final concentration of 8 units / ml and incubated at 37°C for 5 minutes. The DNA was then recovered using the GeneJET PCR Purification Kit (Thermo Fisher Scientific) and precipitated in 20 μl of 1X Exonuclease III (NEB) (50 units) was then added and incubated at 37°C for 20 minutes, followed by heat inactivation at 65°C for 30 minutes.

[0315] Exonuclease III can initiate unidirectional 3'>5' degradation of one DNA strand by using a blunt end or a 5' overhang, producing single-stranded DNA and nucleotides; it is inactive on single-stranded DNA, so 3' overhangs (e.g., Y-shaped adapter ends) are resistant to degradation. Therefore, the complete double-stranded DNA library that has not been cut by Cas9 (e.g., non-mitochondrial DNA in this case) is not digested by exonuclease III, while the DNA molecules that have been cut by Cas9 (e.g., mitochondrial DNA in this case) are degraded by exonuclease III using its 3'>5' activity from the blunt end cut by Cas9 toward the adapter.

[0316] Thus, unwanted DNA was digested. The remaining intact double-stranded DNA library was then recovered using the GeneJET PCR Purification Kit (Thermo Fisher Scientific) and eluted in 20 μl of 10 mM Tris-Cl pH 8. The samples were then quantified using a Qubit Fluorometer (Life Technologies) and sequenced on a MiSeq system (Illumina).

[0317] Alternatively, as described above, unwanted DNA can be digested and intact DNA recovered, for example by column purification or PCR amplification.

[0318] Example 8: Subtraction followed by exonuclease Bal-31

[0319] In some embodiments, it is desirable to remove the cleaved fragments prior to PCR amplification or sequencing.This example illustrates another method for removing unwanted DNA after Cas9-mediated cleavage by using the exonuclease Bal-31 to degrade the cleaved DNA while retaining the uncut DNA of interest.

[0320] like Fig. 9 As shown, a sequencing library (containing, for example, >95% human DNA (e.g., mitochondrial DNA) targeted to be subtracted and <5% target DNA) is prepared according to conventional methods (including a PCR amplification step). The library (500nM) is then incubated at 37°C for 30 minutes using terminal transferase (NEB) and 3mM dGTP according to the manufacturer's instructions, followed by heat inactivation at 75°C for 20 minutes. The library with the 3' poly-dG tail added is then digested with Cas9, complexed with (e.g., a guide RNA library for mitochondrial DNA in this case), as described above, and then heat inactivated at 75°C for 20 minutes. The reaction is then diluted 1:5 in 1x exonuclease Bal-31 reaction buffer (NEB), supplemented with 10 units of exonuclease Bal-31 (NEB), and incubated at 37°C for 30 minutes.

[0321] Exonuclease Bal-31 has two activities: double-stranded DNA exonuclease activity and single-stranded DNA / RNA endonuclease activity. Double-stranded DNA exonuclease activity allows BAL-31 to degrade DNA from the open end on both strands, thereby reducing the size of double-stranded DNA. The longer the incubation time, the more the size of double-stranded DNA is reduced, making it useful for cutting off medium to large DNA (>200bp). It should be noted that the single-stranded endonuclease activity of BAL-31 enables it to quickly digest poly-A, poly-C or poly-T, but digestion of poly-G is extremely low (Marrone and Ballantyne, 2008). Due to this property, adding single-stranded poly-dG at the 3' end of the library can protect BAL-31 from degradation, which we have verified using PCR products. Therefore, DNA molecules that have been cut by Cas9 (for example, mitochondrial DNA in this case) will be degraded by BAL-31 using its double-stranded DNA nuclease activity from the double-stranded blunt end cut by Cas9 toward the other end carrying poly-dG, resulting in attenuation; while the intact DNA library that has not been cut by Cas9 (for example, non-mitochondrial DNA in this case) will not be digested by BAL-31 because they have 3' terminal poly-dG protection.

[0322] After incubation with exonuclease Bal-31, the reaction mixture was heat inactivated at 75°C for 20 minutes, and the DNA was recovered using the GeneJET PCR Purification Kit (Thermo Fisher Scientific). The samples were then quantified using a Qubit fluorometer (Life Technologies) and sequenced on a MiSeq system (Illumina).

[0323] Alternatively, as described above, unwanted DNA can be digested and intact DNA recovered, for example by column purification.

[0324] Example 9: Cas9 depletion and biotin labeling

[0325] In some embodiments, the products of Cas9 cleavage are removed (e.g., >95% mitochondrial DNA is removed), and uncut (<5% target DNA) DNA containing a biotinylated label is purified by binding to streptavidin beads. This example illustrates a method for removing unwanted DNA after Cas9-mediated cleavage without the use of an exonuclease, and Fig.10 Shown in.

[0326] Following conventional protocols, the DNA mixture (containing >95% unwanted human DNA and <5% other target DNA) was fragmented, end-repaired and ligated to adapters, then amplified by PCR using biotin-P5 primers (5' biotin-AATGATACGGCGACCACCGA) and P7 (5'-CAAGCAGAAGACGGCATACGA). This ensures that the entire sequencing library has a 5' biotin label only at one end of the DNA molecule. The DNA mixture was then digested with Cas9 and complexed with (for example, in this case, a guide RNA library for mitochondrial DNA (unwanted DNA)) as described above. The Cas9 reaction was diluted 1:3 with TE (10mM Tris-Cl pH 8, 1mM EDTA), supplemented with 0.5% RNase A (ThermoFisher Scientific) and incubated at 37°C for 5 minutes. Proteinase K (NEB) was then added at a final concentration of 8 units / ml and incubated at 37°C for 5 minutes. DNA molecules cut by Cas9 (e.g., mitochondrial DNA in this case) lose the biotin-labeled adapter and therefore cannot be sequenced or PCR amplified; whereas intact DNA libraries that are not cut by Cas9 (e.g., non-mitochondrial target DNA in this case) still carry the biotin label. Therefore, intact DNA that is not cut by Cas9 can be recovered by adding streptavidin beads (Dynabeads MyOne Streptavidin C1, Thermo Fisher Scientific) to a final concentration of 2%. The beads were captured using a magnetic support and washed 4 times with TE buffer. DNA was released from the beads by heating to 95°C for 3 minutes, followed by 6 PCR cycles using P5 and P7 primers (non-biotinylated). The DNA was then purified using a GeneJET PCR purification kit (Thermo Fisher Scientific). The samples were then quantified using a Qubit fluorometer (Life Technologies) and sequenced on a MiSeq system (Illumina).

[0327] Example 10: Improving the efficiency of Cas9-mediated depletion using thermostable Cas9

[0328] Although Cas9 can be used in conjunction with guide RNA libraries to effectively deplete a pool of target DNA, large amounts (>30 pmole) of Cas9 and guide RNA are required. The reason for this typically >100-fold excess relative to the target DNA is that, unlike classical restriction enzymes such as EcoRI, which completely dissociate from their target DNA after cleavage, Cas9 does not recycle after the cleavage reaction is complete. Cas9 can remain tightly bound to one of the two daughter DNA product molecules (see Fig.11 , open circles on the left). Therefore, more Cas9 and gRNA need to be provided to achieve complete elimination of unwanted DNA. To overcome this problem, thermostable Cas9 (defined as those with >90% activity after 1 minute at 95°C) complexed with guide RNA (e.g., a gRNA library targeting human DNA) can be applied to a sequencing library of a DNA mixture (containing, for example, 95% human DNA and 5% viral DNA). Fig.11 As shown (grey circles on the right), after allowing Cas9 to digest for a period of time, the sample mixture can be boiled, which causes DNA denaturation and dissociation of gRNA and Cas9 from the DNA target. The binding of Cas9 to gRNA can be increased, allowing Cas9-gRNA to dissociate from the DNA target as a complete complex despite DNA denaturation. Dimethyl sulfoxide can be added to reduce the temperature required for DNA denaturation so that the Cas9 protein structure is not affected. Cas9 will preferentially bind to uncut target sites, and thermostable Cas9 will retain activity after boiling. Due to these characteristics, by boiling the reaction and cooling it to 37°C, the thermostable Cas9 will remain able to bind to its gRNA and cut more of its substrate. By allowing recycling of Cas9, the elimination efficiency is improved, and because less Cas9 is required in the reaction, the probability of off-target (non-specific) cutting is also reduced.

[0329] Two exemplary methods for making isothermal Cas9 are provided.

[0330] The first approach is to isolate thermostable Cas9. The genes for thermostable Cas9 and its corresponding guide RNA will be identified by sequence homology in the genomes of thermophilic bacteria Streptococcus thermophilus and Pyrococcus furiosus. The Cas9 gene will then be cloned into the expression vector pET30 (Novagen) to express Cas9 as described in the previous section. The guide RNA sequence will be assembled into oligonucleotides and synthesized (IDT). The active combination of Cas9 and guide RNA will be evaluated by digesting the sequenced DNA template at 37°C (control) and digesting at 95°C for 3X5 minutes followed by digestion at 37°C.

[0331] The second approach is the in vitro evolution of S. pyogenes Cas9. The sequence of Cas9 is mutated to improve its thermostability. Briefly, this is done by site-directed mutagenesis to remove excess loop sequences, increase the number of ionic bridges between protein domains, or by dilution into droplets and PCR to generate a library of potential mutants. All mutants will be evaluated for activity and thermostability as described above.

[0332] Example 11: Monitoring for the reduction of unwanted DNA and off-target events

[0333] In the embodiments discussed, it is desirable to provide positive and / or negative controls. Positive controls will ensure that the elimination of unwanted DNA is performed with fidelity and efficiency. Negative controls will ensure that off-target cleavage is kept to a minimum or is absent.

[0334] A positive control can consist of a sequencing library with an insert containing the target sequence of all or most of the gRNAs included in the kit. This control would be run along with the user's reaction to ensure that all components are working properly. After subtraction with Cas9, the removal of the target sequence can be measured by gel electrophoresis or qPCR.

[0335] Negative controls can include 1) a set of gRNAs with less than 100% identity to the gRNA used in the kit; e.g., 1, 2, 3, 4, 5, or more mismatches to the target-specific sequence; or 2) a DNA library with inserts with less than 100% identity to the targeting sequence of the gRNA used in the kit; e.g., 1, 2, 3, 4, 5, or more mismatches to the complementary sequence of the gRNA. This control will be run along with the user's reaction to ensure that all components are working properly and to measure any off-target activity of the enzyme. After subtraction with Cas9, the amount of off-target subtraction is measured by gel electrophoresis or qPCR.

[0336] In summary, the present invention includes but is not limited to the following items:

[0337] 1. A method for enriching a sample for a target sequence, comprising:

[0338] a. providing a sample comprising a sequence of interest and a sequence targeted to be eliminated, wherein the sequence of interest accounts for less than 30% of the sample;

[0339] b. contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to the targeting sequence and thereby cuts the targeting sequence.

[0340] 2. The method of claim 1, further comprising extracting the target sequence and the sequence targeted for elimination from the sample.

[0341] 3. The method of item 2, which also includes fragmenting the extracted sequence.

[0342] 4. The method of item 3, further comprising connecting the 5' and 3' end adapters of the fragmented extraction sequence.

[0343] 5. The method of claim 1 , wherein the cleaved targeting sequence is removed by size exclusion or by using biotin.

[0344] 6. The method of item 1, which also includes amplifying the target sequence.

[0345] 7. The method of claim 1, wherein the method comprises using at least 10 2 A specific CRISPR / Cas system protein-gRNA complex is contacted with the sample.

[0346] 8. The method of claim 1, wherein the sample is any one of a biological sample, a clinical sample, a forensic sample, or an environmental sample.

[0347] 9. The method of claim 1 , wherein the sample comprises a host nucleic acid sequence targeted for elimination and a non-host nucleic acid sequence of interest.

[0348] 10. The method of claim 9, wherein the non-host nucleic acid sequence comprises a microbial nucleic acid sequence.

[0349] 11. The method of claim 10, wherein the microbial nucleic acid sequence is a bacterial, viral or eukaryotic parasitic nucleic acid sequence.

[0350] 12. The method of claim 1 , wherein the sample is contacted with a CRISPR / Cas system protein-gRNA complex, wherein the gRNA is complementary to mitochondrial DNA.

[0351] 13. The method of claim 1, wherein the sample is contacted with a CRISPR / Cas system protein-gRNA complex, wherein the gRNA is complementary to a DNA corresponding to a ribosomal RNA sequence, a sequence encoding a globulin, a sequence encoding a transposon, a sequence encoding a retroviral sequence, a sequence comprising a telomeric sequence, a sequence comprising a subtelomeric repeat, a sequence comprising a centromere sequence, a sequence comprising an intronic sequence, a sequence comprising an Alu repeat, a sequence comprising a SINE repeat, a sequence comprising a LINE repeat, a sequence comprising a dinucleic acid repeat, a sequence comprising a trinucleic acid repeat, a sequence comprising a tetranucleic acid repeat, a sequence comprising a poly A repeat, a sequence comprising a poly T repeat, a sequence comprising a poly C repeat, a sequence comprising a poly G repeat, a sequence comprising an AT-rich sequence, or a sequence comprising a GC-rich sequence.

[0352] 14. The method of item 2, wherein the extracted nucleic acid comprises any one of single-stranded DNA, double-stranded DNA, single-stranded RNA, double-stranded RNA, cDNA, synthetic DNA, artificial DNA and DNA / RNA hybrid.

[0353] 15. The method of claim 1 , wherein the target sequence accounts for less than 10% of the extracted nucleic acid.

[0354] 16. The method of claim 1, wherein the CRISPR / Cas system protein is Cas9.

[0355] 17. The method of claim 1 , wherein the CRISPR / Cas system protein is catalytically inactive.

[0356] 18. The method of claim 17, wherein the catalytically inactive CRISPR / Cas system protein is dCas9.

[0357] 19. The method of claim 1, wherein the CRISPR / Cas system protein is a CRISPR / Cas system protein nickase.

[0358] 20. The method of claim 19, wherein the CRISPR / Cas system protein is a Cas9 nickase.

[0359] 21. The method of claim 1, wherein the CRISPR / Cas system protein is thermostable.

[0360] 22. The method of item 1, further comprising amplifying the product of step (b) using linker-specific PCR.

[0361] 23. The method of item 1, which also includes treating the product of step (b) with an enzyme having exonuclease activity.

[0362] 24. The method of claim 23, wherein the enzyme is exonuclease III or BAL-31.

[0363] 25. The method of claim 1, wherein the sample is selected from the group consisting of whole blood, plasma, serum, tears, saliva, mucus, cerebrospinal fluid, teeth, bones, nails, feces, urine, tissue and biopsy samples.

[0364] 26. A method for enriching a sample, comprising:

[0365] a. providing a sample comprising a host nucleic acid and a non-host nucleic acid, wherein the host nucleic acid and the non-host nucleic acid are connected by a linker, and wherein the linker is connected to the 5' and 3' ends of the host nucleic acid and the non-host nucleic acid;

[0366] b. contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to a target site in a host nucleic acid, thereby generating a host nucleic acid with an adapter attached only on one end and a non-host nucleic acid with an adapter attached on both the 5' and 3' ends; and

[0367] c. Enrich the sample for non-host nucleic acids.

[0368] 27. The method of claim 26, wherein the method comprises mixing the sample with 10 2A specific CRISPR / Cas system protein-gRNA complex contacts.

[0369] 28. The method of claim 26, wherein the nucleic acid is DNA, and wherein the contacting of step (b) produces a host nucleic acid with an adapter attached to the 5' end but not the 3' end and a non-host nucleic acid with an adapter attached to both the 5' and 3' ends.

[0370] 29. The method of claim 26, wherein the CRISPR / Cas system protein is Cas9, Cpf1, Cas3, Cas8a-c, Cas10, Cse1, Csy1, Csn2, Cas4, Csm2, or Cm5.

[0371] 30. The method of claim 29, wherein the CRISPR / Cas system protein is Cas9.

[0372] 31. The method of claim 26, wherein the CRISPR / Cas system protein is dCas9.

[0373] 32. The method of claim 26, wherein the CRISPR / Cas system protein is a Cas9 nickase.

[0374] 33. The method of claim 26, wherein the CRISPR / Cas system protein is thermostable.

[0375] 34. The method of item 26, wherein the host is selected from the group consisting of humans, cows, horses, sheep, pigs, monkeys, dogs, cats, gerbils, birds, mice and rats.

[0376] 35. The method of claim 26, wherein the non-host is a prokaryotic organism.

[0377] 36. The method of item 26, wherein the non-host is selected from the group consisting of eukaryotes, viruses, bacteria, fungi and protozoa.

[0378] 37. The method of claim 26, wherein the host nucleic acid and non-host nucleic acid connected by the linker are 50-1000 bp.

[0379] 38. The method of claim 26, wherein the non-host nucleic acid accounts for less than 50% of the total nucleic acid in the sample.

[0380] 39. The method of claim 26, wherein the sample is any one of a biological sample, a clinical sample, a forensic sample, or an environmental sample.

[0381] 40. The method of claim 26, wherein step (c) comprises amplifying the product of step (b) using linker-specific PCR.

[0382] 41. The method of claim 26, wherein step (c) comprises treating the product of step (b) with an enzyme having exonuclease activity.

[0383] 42. The method of claim 41, wherein the enzyme is exonuclease III or BAL-31.

[0384] 43. The method of claim 26, wherein step (c) comprises removing host nucleic acids by size exclusion.

[0385] 44. The method of claim 26, wherein step (c) comprises removing host nucleic acid by using biotin.

[0386] 45. The method of claim 26, further comprising amplifying the product of step (b) using linker-specific PCR.

[0387] 46. ​​The method of claim 26, further comprising treating the product of step (b) with an enzyme having exonuclease activity.

[0388] 47. The method of claim 46, wherein the enzyme is exonuclease III or BAL-31.

[0389] 48. The method of claim 26, further comprising using a positive control target sequence.

[0390] 49. The method of claim 26, further comprising using a negative control gRNA.

[0391] 50. The method of claim 26, wherein the sample is selected from the group consisting of whole blood, plasma, serum, tears, saliva, mucus, cerebrospinal fluid, teeth, bones, nails, feces, urine, tissue, and biopsy samples.

[0392] 51. A method for continuously subtracting a target nucleic acid in a sample, comprising:

[0393] a. providing a sample comprising host nucleic acid and non-host nucleic acid, wherein the non-host nucleic acid comprises nucleic acid from at least one known non-host organism and nucleic acid from at least one unknown non-host organism;

[0394] b. contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is configured to hybridize with a target sequence in a host nucleic acid, thereby cleaving a portion of the host nucleic acid;

[0395] c. contacting the sample with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is configured to hybridize to a targeting sequence in at least one known non-host nucleic acid, thereby cleaving a portion of the at least one known non-host nucleic acid; and

[0396] d. isolating the nucleic acid from an unknown non-host organism.

[0397] 52. The method of claim 51, wherein the method comprises mixing the sample with at least 10 2 The invention relates to a method for contacting a specific CRISPR / Cas system protein-gRNA complex, which is configured to hybridize to a target sequence in a host nucleic acid.

[0398] 53. The method of claim 51, wherein the method comprises mixing the sample with at least 10 2 The method further comprises contacting a particular CRISPR / Cas system protein-gRNA complex, wherein the CRISPR / Cas system protein-gRNA complex is configured to hybridize to a target sequence in the at least one known non-host nucleic acid.

[0399] 54. The method of claim 51, wherein the sample is selected from the group consisting of whole blood, plasma, serum, tears, saliva, mucus, cerebrospinal fluid, teeth, bones, nails, feces, urine, tissue and biopsy samples.

[0400] 55. The method of claim 51, wherein the nucleic acid from the unknown non-host organism comprises less than 5% of the total nucleic acid in the sample.

[0401] 56. The method of claim 51, wherein the host is a human.

[0402] 57. A composition comprising a mixture of DNA from a first genome and DNA from a second genome, wherein the first genome DNA and the second genome DNA are linker-connected, and wherein the first genome DNA is complexed with a gRNA-CRISPR / Cas system protein complex.

[0403] 58. The composition of claim 57, wherein the first genome is from a host organism and the second genome is from a non-host organism.

[0404] 59. The composition of claim 57, wherein the CRISPR / Cas system protein is Cas9.

[0405] 60. The composition of claim 57, wherein the CRISPR / Cas system protein is thermostable.

[0406] 61. A kit comprising:

[0407] a. CRISPR / Cas system proteins; and

[0408] b. gRNA, wherein the gRNA is complementary to mitochondrial DNA.

[0409] 62. A kit comprising:

[0410] a. CRISPR / Cas system proteins;

[0411] b. gRNA, wherein the gRNA is complementary to a target of interest; and

[0412] c. An enzyme having exonuclease activity.

[0413] 63. A kit comprising:

[0414] a. a CRISPR / Cas system protein, wherein the CRISPR / Cas system protein is thermostable; and

[0415] b. gRNA, wherein the gRNA is complementary to a target of interest.

[0416] 64. A kit comprising:

[0417] a. CRISPR / Cas system proteins; and

[0418] b. a first gRNA group, wherein the gRNA is complementary to a target sequence of interest; and

[0419] c. Control reagent group.

[0420] 65. The kit of claim 64, further comprising a positive control reagent set.

[0421] 66. The kit of claim 64, further comprising a negative control reagent set.

[0422] 67. A kit comprising:

[0423] a. Reagents for isolating DNA from a cell population;

[0424] b. Insertion enzyme;

[0425] c. CRISPR / Cas system proteins; and

[0426] d. Multiple gRNAs, wherein the gRNAs are complementary to mitochondrial DNA.

[0427] 68. The kit of any one of items 61-67, wherein the CRISPR / Cas system protein is Cas9.

[0428] 69. A kit according to any one of items 61 to 67, comprising at least 10 2 A special gRNA.

[0429] 70. The kit of any one of items 61-67, further comprising a collection of Y-shaped linkers or poly-G linkers. Sequence Listing <110> ARC BIO, LLC <120> Compositions and methods for targeted depletion, enrichment, and fragmentation of nucleic acids using CRISPR / Cas system proteins <130> PDK03562D1 <140> 202111423939.5 <141> 2015-12-19 <150> US 62 / 198,097 <151> 2015-07-28 <150> US 62 / 094,980 <151> 2014-12-20 <160> 102 <170> FastSEQ version 4.0 for Windows <210> 1 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 1 aatgatacgg cgaccaccga 20 <210> 2 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 2 caagcagaag acggcatacg a 21 <210> 3 <211> 18 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 3 cagagcgagg tatgtagg 18 <210> 4 <211> twenty three <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <220> <221> misc_feature <222> 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 <223> n = A, T, C or G <400> 4 nnnnnnnnnn nnnnnnnnnn ngg 23 <210> 5 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <220> <221> misc_feature <222> 28 <223> Can be present or absent <220> <221> misc_feature <222> 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48 <223> n = A, T, C or G <400> 5 gcctcgagct aatacgactc actataggnn nnnnnnnnnn nnnnnnnn 48 <210> 6 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 6 ggatttatac agcactttaa 20 <210> 7 <211> 49 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 7 gcctcgagct aatacgactc actataggct cttaaaacta ggcggctag 49 <210> 8 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 8 gcctcgagct aatacgactc actatagatt tacactcaca acaccctg 48 <210> 9 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 9 gcctcgagct aatacgactc actatagaac agctatccat tggtcttg 48 <210> 10 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 10 gcctcgagct aatacgactc actataggca gccggaagcc tattcgcg 48 <210> 11 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 11 gcctcgagct aatacgactc actataggta atgaggatgt aagcccgg 48 <210> 12 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 12 gcctcgagct aatacgactc actatagata tttacaagag gaaaaccg 48 <210> 13 <211> 49 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 13 gcctcgagct aatacgactc actataggtt tgaagcttag ggagagctg 49 <210> 14 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 14 gcctcgagct aatacgactc actataggta tggctttgaa gaaggcgg 48 <210> 15 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 15 gcctcgagct aatacgactc actatagtag atgacgggtt gggccagg 48 <210> 16 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 16 gcctcgagct aatacgactc actatagagc tttacagtgg gctctagg 48 <210> 17 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 17 gcctcgagct aatacgactc actatagatg gcagcttctg tggaacgg 48 <210> 18 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 18 gcctcgagct aatacgactc actataggtg gtaagggcga tgagtgtg 48 <210> 19 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 19 gcctcgagct aatacgactc actatagtcc ataacgctcc tcatactg 48 <210> 20 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 20 gcctcgagct aatacgactc actatagtct cccttcacca tttccgag 48 <210> twenty one <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> twenty one gcctcgagct aatacgactc actataggcc tatgagtgac tacaaaag 48 <210> twenty two <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> twenty two gcctcgagct aatacgactc actatagctt tgccgcctgc gaagcagg 48 <210> twenty three <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> twenty three gcctcgagct aatacgactc actatagatg tctccatcta ttgatgag 48 <210> twenty four <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> twenty four gcctcgagct aatacgactc actataggga ggcctgcccc cgctaacg 48 <210> 25 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 25 gcctcgagct aatacgactc actatagcga gccgagctgg gccagccg 48 <210> 26 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 26 gcctcgagct aatacgactc actataggcg agcaggagta ggagagag 48 <210> 27 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 27 gcctcgagct aatacgactc actatagcaa cactttctcg gcctatcg 48 <210> 28 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 28 gcctcgagct aatacgactc actatagact ttgacaaagt tatgaaag 48 <210> 29 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 29 gcctcgagct aatacgactc actatagtca aatcaattgg ccaccaag 48 <210> 30 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 30 gcctcgagct aatacgactc actatagact cattcaacca atagcccg 48 <210> 31 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 31 gcctcgagct aatacgactc actataggtg ctcacacgat aaaccctg 48 <210> 32 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 32 aaaacttcta aacgctaatc caagcct 27 <210> 33 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 33 aaaactagcc gcctagtttt aagagct 27 <210> 34 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 34 aaaacagggt gttgtgagtg taaatct 27 <210> 35 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 35 aaaacaagac caatggagatag ctgttct 27 <210> 36 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 36 aaaacgcgaa taggcttccg gctgcct 27 <210> 37 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 37 aaaaccgggc ttacatcctc attacct 27 <210> 38 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 38 aaaacggttt tcctcttgta aatatct 27 <210> 39 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 39 aaaacagctc tccctaagct tcaaact 27 <210> 40 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 40 aaaaccgccttcttcaaagc catacct 27 <210> 41 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 41 aaaacctggc ccaacccgtc atctact 27 <210> 42 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 42 aaaacctaga gcccactgta aagctct 27 <210> 43 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 43 aaaaccgttc cacagaagct gccatct 27 <210> 44 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 44 aaaacacact catcgccctt accacct 27 <210> 45 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 45 aaaacagtat gaggagcgtt atggact 27 <210> 46 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 46 aaaactcgga aatggtgaag ggagact 27 <210> 47 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 47 aaaacttttg tagtcactca taggcct 27 <210> 48 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 48 aaaacctgct tcgcaggcgg caaagct 27 <210> 49 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 49 aaaactcatc aatagatggagacatct 27 <210> 50 <211> 26 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 50 aaaacgttag cgggggcagg cctcct 26 <210> 51 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 51 aaaacggctg gcccagctcg gctcgct 27 <210> 52 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 52 aaaactctct cctactcctg ctcgcct 27 <210> 53 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 53 aaaacgatag gccgagaaag tgttgct 27 <210> 54 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 54 aaaactttca taactttgtc aaagtct 27 <210> 55 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 55 aaaacttggt ggccaattga tttgact 27 <210> 56 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 56 aaaacgggct attggttgaa tgagtct 27 <210> 57 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 57 aaaacagggtttatcgtgtg agcacct 27 <210> 58 <211> 94 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 58 gttttagagc tagaaatagc aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt 60 ggcaccgagt cggtgctttt tttggatccg atgc 94 <210> 59 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 59 gcctcgagct aatacgactc ac 22 <210> 60 <211> twenty one <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 60 aaaaaaagca ccgactcggt g 21 <210> 61 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 61 gcctcgagct aatacgactc actataggtc agtgggggtg aggtaaaa 48 <210> 62 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 62 gcctcgagct aatacgactc actataggct gatcctccaa atcaccac 48 <210> 63 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 63 gcctcgagct aatacgactc actataggtt ggtatcctag tgggtgag 48 <210> 64 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 64 gcctcgagct aatacgactc actataggtt agcctagcca caccccca 48 <210> 65 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 65 gcctcgagct aatacgactc actatagggc cgttaaacat gtgtcac 47 <210> 66 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 66 gcctcgagct aatacgactc actataggtt agcgatggag gtaggat 47 <210> 67 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 67 gcctcgagct aatacgactc actataggta taacctcccc caaaattc 48 <210> 68 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 68 gcctcgagct aatacgactc actataggca ttgcgagacg ctggagc 47 <210> 69 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 69 gcctcgagct aatacgactc actatagaaa agataaaatt tgaaatc 47 <210> 70 <211> 46 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 70 gcctcgagct aatacgactc actatagggt ttatcgatta cagaac 46 <210> 71 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 71 gcctcgagct aatacgactc actatagaaa tctcctaagt gtaagtt 47 <210> 72 <211> 46 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 72 gcctcgagct aatacgactc actatagggg atttagaggg ttctgt 46 <210> 73 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 73 gcctcgagct aatacgactc actataggaa aggttaaaaa aagtaaa 47 <210> 74 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 74 gcctcgagct aatacgactc actatagagg gtttacgacc tcgatgt 47 <210> 75 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 75 gcctcgagct aatacgactc actataggag ggtgatggta gatgtgg 47 <210> 76 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 76 gcctcgagct aatacgactc actataggat aaatcatatt atggcca 47 <210> 77 <211> 46 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 77 gcctcgagct aatacgactc actataggga atgctggaga ttgtaa 46 <210> 78 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 78 gcctcgagct aatacgactc actatagaaa ttaagaatgg ttatgtt 47 <210> 79 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 79 gcctcgagct aatacgactc actataggtt tgtgggttta agtcccat 48 <210> 80 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 80 gcctcgagct aatacgactc actataggtg atgccagcag ctaggac 47 <210> 81 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 81 gcctcgagct aatacgactc actataggtt caccgtaggt ggcctgac 48 <210> 82 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 82 gcctcgagct aatacgactc actatagtgg agggttcttc tactatt 47 <210> 83 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 83 gcctcgagct aatacgactc actataggtg ttaggaaaag ggcatac 47 <210> 84 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 84 gcctcgagct aatacgactc actatagatc tgtttttaag cctaatg 47 <210> 85 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 85 gcctcgagct aatacgactc actataggtt gtgtttaata tttttagt 48 <210> 86 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 86 gcctcgagct aatacgactc actataggtg gttggtgtaa atgagtg 47 <210> 87 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 87 gcctcgagct aatacgactc actataggaa aacgtaggct tggatta 47 <210> 88 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 88 gcctcgagct aatacgactc actatagggc cagtgccctc ctaattg 47 <210> 89 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 89 gcctcgagct aatacgactc actatagaaa tccacccctt acgagtg 47 <210> 90 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 90 gcctcgagct aatacgactc actataggca tttaccatct cacttct 47 <210> 91 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 91 gcctcgagct aatacgactc actatagata aaatatgatt agttctg 47 <210> 92 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 92 gcctcgagct aatacgactc actataggta ggagagtgat atttgatc 48 <210> 93 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 93 gcctcgagct aatacgactc actatagggt atgagttttt tttgtta 47 <210> 94 <211> 48 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 94 gcctcgagct aatacgactc actataggcc tctcagccga tgaacagt 48 <210> 95 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 95 gcctcgagct aatacgactc actatagagt gttagagttt ggattag 47 <210> 96 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 96 gcctcgagct aatacgactc actataggtt tgtgtatgat atgtttg 47 <210> 97 <211> 46 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 97 gcctcgagct aatacgactc actataggga gtagggttag gatgag 46 <210> 98 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 98 gcctcgagct aatacgactc actataggac ctagttcaat gaatctg 47 <210> 99 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 99 gcctcgagct aatacgactc actataggga cgcctcctag tttgtta 47 <210> 100 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 100 gcctcgagct aatacgactc actataggca ggtgtctcct ctatctt 47 <210> 101 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 101 gcctcgagct aatacgactc actataggat tcaaattatg tgttttt 47 <210> 102 <211> 47 <212> DNA <213> Artificial sequence <220> <223> Synthetic constructs <400> 102 gcctcgagct aatacgactc actatagtca tctccggttt acaagac 47

Claims

1. A method for enriching a sample, include: a. Providing nucleic acid extracted from a sample, wherein the extracted nucleic acid comprises host nucleic acid and non-host nucleic acid; b. fragmenting the extracted nucleic acid; c. ligating the host nucleic acid and the non-host nucleic acid to a linker, wherein the linker is linked to both the 5' and 3' ends of the host nucleic acid and the non-host nucleic acid; d. contacting the product of step (c) with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is complementary to a target site in a host nucleic acid, thereby generating a cleaved host nucleic acid fragment with an adapter attached to only one end, and leaving a non-host nucleic acid with an adapter attached to both the 5' and 3' ends uncut; and e. Amplify the product of step (d) using adapter-specific PCR to enrich for uncleaved non-host nucleic acids in the sample.

2. The method according to claim 1, wherein the method comprises contacting the sample with at least 10 2 A specific CRISPR / Cas system protein-gRNA complex contacts.

3. The method according to claim 1, wherein the CRISPR / Cas system protein is Cas9, Cpf1, Cas3, Cas8a-c, Cas10, Cse1, Csy1, Csn2, Cas4, Csm2 or Cm5.

4. The method according to claim 3, wherein the CRISPR / Cas system protein is Cas9 or Cpf1.

5. The method according to claim 1, wherein the CRISPR / Cas system protein is thermostable.

6. The method according to claim 1, wherein the host is selected from the group consisting of humans, cows, horses, sheep, pigs, monkeys, dogs, cats, gerbils, birds, mice and rats.

7. The method according to claim 1, wherein the non-host is selected from the group consisting of eukaryotes, prokaryotes, and viruses.

8. The method according to claim 1, wherein the host nucleic acid and non-host nucleic acid connected by the adapter are 50-1000 bp.

9. The method of claim 1, wherein the non-host nucleic acid comprises less than 50% of the total nucleic acid in the sample.

10. The method according to claim 1, wherein the sample is any one of a biological sample, a clinical sample, a forensic sample or an environmental sample.

11. The method according to claim 1, further comprising treating the product of step (d) with exonuclease III, wherein the linker is Y-shaped.

12. The method according to claim 11, further comprising treating the product of step (d) with BAL-31, wherein the linker comprises a poly-G tail.

13. The method according to claim 1, wherein the sample is selected from the group consisting of whole blood, plasma, serum, tears, saliva, mucus, cerebrospinal fluid, teeth, bone, nail, stool, urine, tissue and biopsy samples.

14. A method for continuously depleting a target nucleic acid in a sample, include: a. providing a sample of nucleic acids extracted from a sample, wherein the nucleic acids comprise host nucleic acids and non-host nucleic acids, wherein the non-host nucleic acids comprise nucleic acids from at least one known non-host organism and nucleic acids from at least one unknown non-host organism; b. fragmenting the extracted nucleic acid; c. ligating the host nucleic acid and the non-host nucleic acid to a linker, wherein the linker is linked to the 5' and 3' ends of both the host nucleic acid and the non-host nucleic acid to generate a linker-ligated nucleic acid; d. contacting the product of step (c) with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is configured to hybridize to a target sequence in a host nucleic acid, thereby cleaving a portion of the host nucleic acid, thereby generating a cleaved host nucleic acid fragment with only an adapter attached to one end, and leaving a non-host nucleic acid with an adapter attached to both the 5' and 3' ends uncut; e. contacting the product of step (d) with a plurality of CRISPR / Cas system protein-gRNA complexes, wherein the gRNA is configured to hybridize to a target sequence in at least one known non-host nucleic acid, thereby cleaving a portion of the at least one known non-host nucleic acid, thereby generating cleaved known non-host nucleic acid fragments with an adapter attached to only one end, and leaving nucleic acid from the at least one unknown non-host organism with an adapter attached to both the 5' and 3' ends uncut; and f. Amplifying the product of step (e) using adapter-specific PCR to isolate nucleic acid from the unknown non-host organism.

15. The method according to claim 14, wherein the method comprises exposing the sample to at least 10 2 The invention relates to a method for contacting a specific CRISPR / Cas system protein-gRNA complex, which is configured to hybridize to a target sequence in a host nucleic acid.

16. The method according to claim 14, wherein the method comprises exposing the sample to at least 10 2 The method further comprises contacting a particular CRISPR / Cas system protein-gRNA complex, wherein the CRISPR / Cas system protein-gRNA complex is configured to hybridize to a target sequence in the at least one known non-host nucleic acid.

17. The method according to claim 14, wherein the sample is selected from the group consisting of whole blood, plasma, serum, tears, saliva, mucus, cerebrospinal fluid, teeth, bones, nails, stool, urine, tissue and biopsy samples.

18. The method of claim 14, wherein the nucleic acid from the unknown non-host organism comprises less than 5% of the total nucleic acid in the sample.

19. The method according to claim 14, wherein the host is a human.